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INTRODUCTION 
 
 
 
1. THE LIVER 
1.1 Rat Liver 
Rat liver is constituted of four separate lobes, each one having different size and 
weight and named according to their position. The left lateral lobe is situated in left 
lateral position dorso-caudal to the median lobe and cranio-ventral to the caudate lobe 
and the stomach. This lobe has an average weight of 33 g, representing about 30% of 
the total liver mass, is associated to the base of the left portion of the median lobe by 
means of the thin vessels-enclosing pedicle that is in connection to the intrahepatic 
vena cava, and moreover interlobular ligaments link it with the superior caudate lobe. 
The median lobe, which accounts for about 40% (38 g) of the total liver weight, is 
placed under the diaphragm, fixed by means of falciform ligament that is extended 
from the xyphoid and diaphragm to the interlobular fissure. This lobe is characterised 
by a wide base, which surrounds about one half of the circumference of the vena cava, 
and is subdivided in a left part separated to the right part by a deep fissure. The right 
lobe is positioned on the right side of the vena cava, and is possible to distinguish two 
parts, the right superior and the right inferior lobe, the first representing 13% of the 
total liver mass, the latter about 6%. The caudate lobe, or Spiegel lobe, arranged on the 
left part of the vena cava, has an average weight of 7 grams, and consists of two parts, 
superior or upper caudate lobe, and inferior or lower caudate lobe. 
The so-called paracaval liver should not be considered as a definite anatomic part of 
the liver, but rather as a functional assembly of the dorsal bottom portions of the right 
superior, inferior, and caudate lobes. It is bound to the dorsal portion of the diaphragm 
by thin ligaments, and covers the space from the pedicles of the diaphragm to the base 
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of the right inferior lobe. The paracaval liver as a whole represents about 2.5% - 3% of 
the total liver mass (Madrahimov N et al., 2006).  
 
Figure 1  Rat liver lobes: weight distribution (from Madrahimov N et al., 2006). 
 
About the circulatory system of the rat liver, on the functional point of view, two main 
venous systems are recognised, the portal system and the hepatic vein system. The first 
one has two main branches, the right portal vein that furnishes the right liver lobe, and 
the caudate portal vein, which is located on the left side and supplies the caudate lobe. 
A series of subsequent ramifications allow the portal vein to reach all lobes of the 
liver, as depicted below in Figure 2. The paracaval liver is furnished of portal blood 
from three distinctive sources, the left part from subdivisions of the caudate portal 
vein, the right one from the right portal vein, whereas the intermediate and cranial 
tissue from veins deriving from the dorsal wall of the main portal venous stem. The 
subdivisions of the hepatic artery parallel those of portal vein.  
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Figure 2  Rat liver: schematic representation of portal vein anatomy (from Madrahimov N et al., 2006). 
 
The hepatic venous system collects blood from the left and the right part of the liver, 
by means of different veins as represented in Figure 3. The left hepatic vein, which is 
subdivided in a median and a lateral portion, drains the left lateral lobe and the left 
portion of the median lobe. The right median hepatic vein gathers the blood from right 
hemi liver, whereas the caudate vein does the same from the caudate lobe. Numerous 
small veins have the role to collect the blood from the paracaval liver, directing it into 
the intrahepatic part of the vena cava (Madrahimov N et al., 2006).   
 
Figure 3  Rat liver: schematic representation of hepatic vein anatomy (from Madrahimov N et al., 
2006). 
 
1.2 Human Liver 
In humans the liver is located, together with biliary tree and the gallbladder, in the 
right upper quadrant of the abdominal cavity, between the digestive tract and the 
remaining part of the internal organs. From the anatomical point of view, the human 
liver is positioned under the rib cage and covers the space between the right fifth 
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intercostal space and the midclavicular line, below the costal border. In normal adult 
people, the liver weight usually ranges between 1.4 to 1.6 kg, and traditionally was 
subdivided into four separate lobes, right, left, caudate and quadrate. About 25% of 
total blood pumped by the heart it is required to the liver to function properly, and it 
enters the liver for the most part (60%-70%) from the portal vein and for the remaining 
part (30%-40%) from the hepatic artery through the hilum. In the same district arrives 
the major bile duct, whereas the initial right and left branches of the portal vein, 
hepatic artery, and bile duct are positioned immediately external to the liver. The 
remaining part of the circulatory tree runs parallel wise inside the liver in the so-called 
portal tracts, giving rise to 17 to 20 orders of branches; it has been evaluated that 
almost all hepatic parenchyma is supplied thanks to about 4.5•105 terminal branches of 
the portal tract system. Septal venules transport portal vein blood inside parenchyma, 
whereas all the parenchyma, the principal bile ducts, the vasa vasorum of the major 
portal veins and hepatic veins, and the hepatic capsule are supplied by means of 
hepatic arteriolar twigs. Blood collected from all regions into ramification of the 
hepatic vein is brought outside the liver itself through the inferior vena cava. The 
circulatory system of the human liver is depicted in Figure 4. 
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Figure 4  Human liver: schematic representation of circulatory system.  
 
About the microscopic organisation of the human liver, the first well recognised 
structures were the so-called lobules, 1-2 mm diameter roughly hexagonal assemblies, 
situated all-around the terminal hepatic veins, portal tracts being placed at the 
periphery of the lobule. In this way, it is possible to distinguish centrilobular 
hepatocytes, located near the terminal hepatic vein, and periportal hepatocytes, sited 
close to the portal tract. Anyway, considering that hepatocytes in close proximity to 
the terminal hepatic veins are very far from the blood supply, it has been suggested 
that they could be placed at the top of hypothetical triangular acini, the bases of which 
constituted by septal venules that enter from the portal vein spreading from the portal 
tracts. The parenchyma inside the acinus could be subdivided into three distinct zones: 
zone 1, nearest to the vascular supply, zone 3 being adjacent to the terminal hepatic 
venule, and zone 2 in the middle. This sort of “zonation” has been found to have great 
metabolic relevance, considering that several hepatic enzymes show a lobular gradient 
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of activity, and also a lot of types of hepatic injuries have a zonal pattern of 
manifestation (Jungermann K, Kietzmann T, 1996).  
The typical structures of the hepatic parenchyma are the cribriform, anastomosing 
sheets or “plates” of hepatocytes, easily distinguishable as a sort of threads of cells in 
microscopic images. Hepatocytes placed in the near proximity of the portal tract have 
been named as the limiting plate, and they are characterised by the peculiarity to form 
a sort of irregular border around the mesenchyme of the portal tract. Moreover, the 
hepatocytes cords previously described are radially oriented around the terminal 
hepatic vein. 
 
 
Figure 5  Human liver: schematic representation of microscopic organisation of hepatic parenchyma.  
 
Vascular sinusoids are intercalated between the cords of hepatocytes, and are crossed 
by blood, which in turn finds the way out to the terminal hepatic vein passing through 
the orifices of the vein wall. Each sinusoid is delimitated by fenestrated endothelial 
cells that delineate the extra sinusoidal space of Disse, which is rich in hepatocytes 
microvilli. Kupffer cells, which belongs to the mononuclear phagocyte system, are 
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distributed in close proximity of the luminal face of endothelial cells, and the typical 
fat-containing perisinusoidal stellate cells are placed in a disperse manner inside the 
space of Disse. Stellate cells take part in the accumulation and metabolism of vitamin 
A, and when in presence of an inflammatory condition they acquire a myofibroblast 
phenotype, beginning to produce collagen. 
Bile canaliculi are a sort of microscopic channels 1 to 2 µm in diameter connecting 
adjacent hepatocytes, shaped by grooves in the plasma membranes and demarcated 
from the vascular space by means of tight junctions. These intercellular spaces, which 
represent the final branches of the biliary tree, are filled with many microvilli; actin 
and myosin microfilaments that surround canaliculi provide the energy required to 
drive biliary fluid along the canaliculi, until the canals of Hering in the periportal 
region. Biliary fluid is then transferred to bile ductules, and finally to the terminal bile 
ducts within the portal tracts. 
 
 
Figure 6  Human liver: schematic representation of microscopic organisation of hepatic parenchyma, 
with particular reference to circulatory and biliary systems.  
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1.3 Metabolic functions 
In Mammals the liver is probably the most important organ from a metabolic point of 
view, considering that it takes a fundamental part in the metabolism of all nutrient 
molecules and most hormones, in bile formation and excretion, in detoxifications 
reactions of many toxins and drugs (Stryer L, 1997). 
Carbohydrates 
All complex carbohydrates are catabolised to give glucose, fructose and galactose, and 
even if the liver has the ability to metabolise huge quantities of fructose, giving lactate 
as a final product, the most part of fructose and galactose are converted in glucose 
entering in its main metabolic pathway. In the liver (and adipose tissue as well) the 
phosphogluconate pathway is operative too, providing a cofactor essential for the fatty 
acids biosynthetic pathway (Stryer L, 1997). 
The great majority of glucose introduced during a meal is converted and stored as 
glycogen, primarily inside the liver and to a lesser extent in skeletal muscle. Usually in 
Man, the maximum amount of glycogen that can be accumulated inside the liver is 
about 200 g, and when this threshold is surpassed, the liver gets start to the lipogenic 
pathway (Stryer L, 1997). 
The liver and kidney play also an essential role considering their peculiar characteristic 
to possess the biochemical machinery needed to synthesise glucose starting from 
lactate, pyruvate, amino acids (principally alanine) and glycerol. From a physiological 
point of view this ability is of vital importance in maintenance of haematic glucose 
homeostasis, glucocorticoids, catecholamines, glucagon and thyroid hormone 
increasing gluconeogenesis, and insulin reducing it (Stryer L, 1997). 
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Lipids 
The liver is able to stock excess of carbohydrates introduced with diet as glycogen, but 
when these stores become saturated, the lipogenic pathway start to work, converting 
carbohydrates and proteins as well into fatty acids. Hepatocytes can employ these fatty 
acids directly or store them, in synergy with white adipose tissue. Fatty acids can be 
utilised as fuel molecules from most cell types, with the exception of erythrocytes and 
renal medulla, which are strictly glucose-dependent. Brain has not a similar stringent 
dependence on glucose, considering that after several days without it, neurons show 
the ability to catabolise ketone bodies produced by the liver (Stryer L, 1997). 
The final product of fatty acid oxidation is acetyl coenzyme A (acetyl-CoA), which in 
turn enters the citric acid cycle. Under conditions of excess of acetyl-CoA, the liver 
can produce the ketone body acetoacetic acid that can be used by other cell types as an 
energetic substrate, after reconversion into acetyl-CoA. Acetyl-CoA represents the 
principal building block necessary to synthesise cholesterol and phospholipids as well 
(Stryer L, 1997). 
Proteins 
The liver is certainly the key organ in protein metabolism, considering that if some 
block would occur in its functionality consequences at whole organism level could be 
fatal in few days. Four main stages can be summarised, i.e. deamination of amino 
acids, formation of urea, conversion between nonessential amino acids, production of 
plasma proteins (Stryer L, 1997). 
Transamination reactions remove the amino group from amino acids giving the 
respective keto acids as a product. The great majority of amino acids introduced as 
protein from foods are deaminated at the liver level, only very little amounts being 
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processed in the kidneys, and the particular case of branched-chain amino acids 
(leucine, isoleucine, valine) that are catabolised almost exclusively in skeletal muscle. 
For what concerns plasma proteins, excluding immunoglobulin, the liver synthesizes 
the remaining part. From a strictly quantitative point of view, albumin, α1-antitrypsin 
and other proteases and elastases are the most abundant proteins produced by the liver. 
The function of liver in regulating plasma concentration of albumin is indeed very 
important, since this protein binds and transport fatty acids, several hormones and 
drugs, and keeps oncotic pressure in the plasma at normal values (Stryer L, 1997). 
From a qualitative point of view, coagulation factors are without any doubt a class of 
essential proteins that, excluding factor VIII and von Willebrand factor, are all 
synthesized at the hepatic level. In particular it is meaningful to mention the vitamin 
K-dependent biosynthesis of prothrombin or factor II, and of factors VII, IX and X 
(Stryer L, 1997).   
Other central proteins produced by the liver comprise complement, C-reactive protein, 
serum amyloid A, α1-acid glycoprotein, but also transport proteins as transferrin, 
ceruloplasmin and haptoglobin, and protease inhibitors as α1-antitrypsin, α2-
antiplasmin and antithrombin III. To be mentioned is plasma cholinesterase, the so-
called pseudocholinesterase, which hydrolysing esters plays an essential role in the 
clearance of several local anaesthetics and succinylcholine (Stryer L, 1997).  
Figure 7 summarises the principal metabolic pathways that takes place in the liver.  
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Figure 7  Human liver: schematic representation of metabolic pathways.  
 
Drugs 
The liver has certainly to be considered the principal site where exogenous molecules 
and most drugs are catabolised. At the hepatocyte level these substances are 
deactivated and transformed to obtain more water-soluble compounds, which are 
finally excreted through bile and/or urine. 
Two main categories of reactions can be described in this regard, named phase I and 
phase II. Phase I reactions typically are characterised by the direct modification of 
reactive groups, thanks to mixed-function oxidases and/or cytochrome P-450 system, 
finally resulting in oxidations, methylations, deaminations, dealkylations and 
sulfoxidations. Striking examples of drugs cleared through this pathway are 
benzodiazepines, barbiturates, ketamine and ethanol, which are also able to induce the 
synthesis of the enzymes of the cytochrome P-450 system. Phase II reactions, on the 
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other hand, are characterised by conjugation reactions with glycine, taurine, and 
sulphate and glucuronide groups. After conjugation the product can be discarded 
through bile or urine (Stryer L, 1997).  
Other metabolites  
The liver performs several essential metabolic functions for what concerns vitamins, 
minerals and hormones. Vitamins A, B12, E, D and K are stored mainly in the 
hepatocyte, whereas transferrin and haptoglobin, and ceruloplasmin are the key 
proteins that regulate iron and copper balance respectively. Regarding the role in 
hormones metabolism, well known is the function performed on thyroid hormone 
balance, considering that the great majority of triiodothyronine (T3) is produced at the 
hepatic level, as well as all the steps required for its breakdown. Similarly, at the 
hepatic level takes place catabolism of glucagon, antidiuretic hormone, insulin and 
steroid hormones as oestrogens, cortisol and aldosterone (Stryer L, 1997). 
Bile   
Bile has a fundamental part in the processes of fat absorption and cholesterol, bilirubin 
and most drugs elimination. Phospholipids, conjugated bilirubin, cholesterol (0.3%), 
bile salts (10%) and other elements as mucus and pigments (3%), inorganic salts 
(0.7%), are secreted constantly into bile canaliculi. Bile is produced thanks to three 
principal mechanisms: a) Na
+
/K
+
-adenosine triphosphatase-mediated ion transport 
(bile salt-independent fraction), b) osmotic filtration induced by secretion of bile salts 
into canaliculi (bile salt-dependent fraction), c) secretin-mediated sodium and 
bicarbonate transport by ductules. 
Bile produced in this way is directed into the duodenum through the common bile 
duct, formed by the joining of hepatic duct, which comes from connection of right and 
left hepatic ducts originating from hepatic lobules, with cystic duct from the 
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gallbladder. Sphincter of Oddi is deputed to control the biliary flow from the common 
bile duct into the duodenum. The gallbladder has the function to accumulate biliary 
fluid between meals, thanks to active sodium transport and passive water reabsorption. 
When cholecystokinin is liberated from the intestinal mucosa due to protein and fats, 
gallbladder is induced to shrink, sphincter of Oddi undergo to relaxation and bile is 
transferred into the small intestine.  
From the functional point of view, the bile acids play an important role in facilitating 
the absorption of lipids operated by intestine as well as in helping emulsifying 
insoluble components of bile and elimination of cholesterol. The two most important 
bile acids, cholic acid and chenodeoxycholic acid, are conjugated with glycine and 
taurine and, as salts are secreted into bile. Inside the colon they are modified, by 
bacteria, to deoxycholic acid and lithocholic acid respectively, the so-called secondary 
bile acids. These ones play indeed an essential role in vitamin homeostasis, 
considering that any trouble affecting bile salts formation and/or secretion alters the 
normal process of absorption of fats and consequently of fat-soluble vitamins. 
Bilirubin is produced when the haeme ring is degraded inside Kupffer cells, due to the 
action of heme oxygenase that gives back biliverdin, carbon monoxide and iron; 
biliverdin in turn is converted to bilirubin by biliverdin reductase. Once produced 
bilirubin passes in the bloodstream, binds to albumin and thenceforth it enters inside 
hepatocytes, where the binding to intracellular proteins block it inside the cell. The 
hepatocyte possesses the enzymatic machinery needed to conjugate bilirubin with 
glucuronide, permitting the conjugated product to be excreted into bile canaliculi, only 
a minor fraction being reabsorbed into the blood. Once into the intestine, colonic 
bacteria transform about a half of bilirubin in urobilinogen, which in turn is partly 
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reabsorbed by the intestine and brought back to the liver (enterohepatic recirculation), 
and partially excreted through the kidney (Stryer L, 1997).       
                                 
2. THYROID HORMONES and DIIODOTHYRONINES   
2.1 Synthesis and metabolism 
Thyroid gland is an endocrine gland, present in all Vertebrates, starting from adult 
Cyclostomata to Mammals and Man. Its microscopic anatomy is characterised by a 
vesicular structure, organised in oval or spherical cystic follicles, lined by a 
monostratified epithelium, composed by cells with different heights, often cubic in 
shape. The fundamental physiological characteristic of this gland is its peculiar ability 
to concentrate iodine and to use it to synthesize thyroid hormones (Padoa E, 1978). 
Thyroid hormones are synthesized, with similar mechanisms in all Vertebrates, in the 
colloid, a sort of gel that fills the internal part of the thyroid follicles. Iodine, ingested 
with foods, is reduced to iodide ion in the intestine, enters the bloodstream and is 
absorbed into the epithelial thyroid cells. This process is mediated by the Na
+
/I
+
 
transporter, which works using the high Na
+
 extracellular concentration, which is 
produced by the action of Na
+
/K
+
 ATPase pump (Dai G et al., 1996).   
Iodine is transported inside the thyroid follicle together with thyroglobulin, a 660-kDa 
glycoprotein, which contains 134-140 tyrosine residues. Iodine can be bound on about 
a quarter of these residues: this reaction that takes place at the interface between apical 
follicular cells and colloid, is catalysed by thyroid peroxidase (TPO), an haeme-based 
enzyme, localised in the apical plasma membrane of thyroidal epithelial cells. After 
that iodine has been covalently bound, thyroglobulin enters the colloid, where TPO 
also catalyse the coupling reaction between iodinated tyrosine residues: two 
diiodotyrosine lead to formation of thyroxine (3,5,3’,5’-tetraiodothyronine, T4), 
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whereas one diiodotyrosine with one monoiodotyrosine give rise to 3,5,3’-
triiodothyronine or T3 (Yen PM, 2001). 
After synthesis thyroid hormones are cut from thyroglobulin inside lysosomes of 
thyroidal epithelial cells, then diffuse outside lysosomes, and through epithelial cells 
basal membrane, enter the bloodstream (Taurog A, 1996).  
In Man thyroid produces, every day, approximately 100 μg of thyroid hormones, the 
major part being represented by T4 (≈ 90%) and its concentration in the serum is about 
40 times higher with respect to T3 (90 nM vs. 2 nM). Only the 0.03% of total T4 found 
in serum is free, whilst the remaining part is bound to carrier proteins, as thyroxin-
binding globulin (TBG), transthyretin (TTR), thyroxin-binding prealbumin (TBPA) 
and albumin; lesser amounts are bound to lipoproteins as well. For what concerns T3, 
only about 0.3% is free in the serum, whereas the vast majority is transported by TBG, 
albumin, and lipoproteins. TBG is a 64-kDa tetrameric protein, and each monomer 
binds to one single thyronine (Robbins J, 2000). 
In humans roughly 80% of plasmatic T4 is coupled to TBG, 15% to TTR and 5% to 
albumin and lipoproteins, differently to T3, 90% of which is coupled to TBG and the 
remaining 10% to albumin and lipoproteins (Choksi NY et al., 2003). In rodents TBG 
gene is expressed at very low levels and consequently almost all T4 and T3 are found 
bound to albumin and TTR (Kaneko JJ, 1989).  
Once reached the target-organs thyroid hormones enter the cells through specific 
transporters (Hennemann G et al., 2001) or receptors for TBG and TTR (Robbins J, 
2000).                 
The principal pathway leading to T3 production is deiodination at position 5’ of T4 
external ring, operated by deiodinases (Kohrle J, 2000). In man and rodents, about 
10% of T4 is deiodinated to T3 before secretion by deiodinase type I (DI), whereas, for 
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the other 90%, deiodination takes place in the liver and in the kidney. In the brain, 
anterior pituitary gland, skeletal muscle, placenta, and in rodents also in brown adipose 
tissue, deiodinase type II (DII) is responsible for production of small amounts of T3. 
Finally, deiodinase type III (DIII), localised in the brain, placenta, and foetal tissues, in 
man and rodents, is able to perform deiodination only on the inner ring of T4 and T3 
molecules, giving rise to diiodothyronines and to 3,5’, 3’-triiodothyronine or reverse 
T3 (rT3), which can be considered as the first step in the catabolic pathway of thyroid 
hormone (Wassen FW et al., 2004), even if some recent reports suggest that this 
molecule might have some biological effects (Cheng SY et al., 2010). 
In adult men T4 and T3 serum half-lives are, respectively, 5-9 days and 1 day, whereas 
in rats, 12-24 hours and 6 hours (Choksi NY et al., 2003).  
 
 
 
Figure 8  Thyroid hormone: schematic representation of catabolic pathways.  
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2.2 Hypothalamus-Pituitary-Thyroid (HPT) Axis 
Thyroid hormones synthesis and secretion are tightly regulated by a negative feedback 
loop, involving the so-called Hypothalamus-Pituitary-Thyroid (HPT) Axis. This finely 
tuned control mechanism is achieved by the action of two hormones, Thyrotropin 
Releasing Hormone (TRH) produced by hypothalamus, and Thyroid Simulating 
Hormone (TSH), secreted by pituitary gland (Randall D et al., 1997). 
Elevated concentrations of thyroid hormones in blood lead to inhibition of TRH 
production and consequently to a decrease of TSH secretion. It is well known that 
thyroid hormones are able to reduce the responsiveness of thyrotrophic cells to TRH, 
and that the ability of these cells to respond to TRH depends on their T3 internal 
concentration. When T3 levels are low, the number of TRH receptors increases 
inducing an increase in the synthesis of TSH, on the contrary, when in presence of 
higher T3 concentrations, TRH receptors decrease as well as TSH production (Fliers E 
et al., 2006). 
This regulation system is influenced by internal as well as external factors. Concerning 
the internal ones, somatostatin and dopamine negatively regulate TSH secretion in the 
hypothalamus (Samuels MH et al., 1992). One the other hand, among the external 
factors, one of the best known is the effect of changes in the atmospheric temperature 
in man as well as in rat: for example, in man, four days in a cold environment are able 
to induce an increase in the levels of TRH, TSH and as a consequence of circulating 
thyroid hormones, leading to a rise in basal metabolic rate and in heat generation 
(Eastman CJ et al., 1974). Similar results have been observed in rats, after 24h 
exposure to cold (Tuominen RH et al., 1985). Moreover, at the pituitary gland level, is 
well documented the inhibitory effect on TSH secretion induced by glucocorticoids 
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(Wilber JF, Utiger RB, 1969), and the stimulatory one provoked by oestrogens 
(Yarwood NJ et al., 1993).         
 
Figure 9  Thyroid hormone: schematic representation of Hypothalamus-Pituitary-Thyroid (HPT) axis. 
 
2.3 Physiological Effects  
In Mammals, thyroid hormones exert a wide variety of fundamental physiological 
effects including regulation of energetic metabolism, body temperature and growth, 
and bone metabolism. Essential are also actions exerted on cardiovascular and central 
nervous systems.   
In almost all tissues, with the exception of brain, spleen and testicles, thyroid 
hormones are able to induce an acceleration of metabolic processes, due to an increase 
of mitochondria number and size and also to a stimulation of synthesis of respiratory 
chain enzymes (Wrutniak-Cabello C et al., 2001). Moreover an increase of Na
+
/K
+
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ATPase molecules has been observed, due to enhanced transcription coupled to 
augmented transport of primary transcripts from the nucleus to the cytoplasm 
(Harrison AP, Clausen T, 1998). It is useful to remember that 15% to 40% of the 
energy produced by cells is consumed to keep the electrochemical gradient across the 
cell membrane, so an intensification of activity of Na
+
/K
+
 ATPase necessarily parallels 
with an increase of basal metabolic rate. 
Important effects have been described on lipid and cholesterol metabolism at the 
hepatic level, where thyroid hormone is able to up regulate malic enzyme, glucose-6-
P-dehydrogenase and fatty acid synthase (Oppenheimer JH et al., 1995), and also acid 
cholesterol ester hydrolase (Severson DL, Fletcher T, 1981) and LDL receptor 
(Scarabottolo L et al., 1986). 
About the role of thyroid hormones in the regulation of carbohydrate metabolism, it 
has been shown that the great majority of the enzymes involved in the gluconeogenesis 
are stimulated (Feng X et al., 2000), together with GLUT4 glucose transporter gene 
expression (Chidakel A et al., 2005).  
Thyroid hormone displays relevant physiological actions on bone metabolism as 
historically described in patients that develop hypothyroidism during childhood, which 
classically show delayed growth and short stature. Deleterious effects on bone mass 
have likewise been reported in hyperthyroidism, which induces lost of thickness and 
increase in porosity (Greenspan SL, Greenspan FS, 1999). 
On the cardiovascular system thyroid hormones reduce systemic vascular resistance, 
and induce vasodilatation, leading to an increase of blood flow. Heart frequency, 
contractility and amount of blood pumped are as well stimulated, as shown examining 
hyper- and hypothyroid patients (Klein I, Ojamaa K, 1998).  
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Fundamental functions are played by thyroid hormones in correct development and 
functionality of brain, both in humans and rats. In Man, neonatal hypothyroidism 
results in mental retardation and neurological defects (Bernal J, 1999). In rats, neonatal 
thyroid hormones deprivation leads to a decrease in axonal growth and dendritic 
spread, in cerebral, watching and hearing cortex, in hippocampus and cerebellum 
(Rabie A et al., 1977). In adults the influence exerted by thyroid hormones is similarly 
very pronounced: hyperthyroidism is able to induce increase of CNS excitability, 
whereas hypothyroidism have the opposite effect, as shown in rats, where reduction in 
response to visual and acoustic stimuli, slowed reflexes, and smaller alpha waves in 
electroencephalogram have been well documented (Padoa E, 1978). 
 
2.4 Way of Action 
Genomic Effects 
Once reached target cells thyroid hormones generate a lot of biological effects, some 
of which described above. 
Historically it was shown that thyroid hormone actions are mediated by nuclear 
receptors (TRs), tightly associated with chromatin and with high affinity and 
specificity for T3. Thyroid hormones enter into the target cell, where T3 is produced by 
deiodination of T4, and in the nucleus it binds to TRs, which are associated to Thyroid 
Response Elements (TREs), found in the promoter region of target genes. Formation 
of T3-TR-TRE complexes is the first step in the process of regulation, positive as well 
as negative, of target genes under thyroid hormone control (Samuels HH et al., 1988).  
TRs are members of the same nuclear receptors superfamily that includes steroid 
hormones, Vitamin D and retinoic acid. In humans, rat, mice, chicken and amphibian, 
two isoforms have been discovered, TRα and TRβ, codified by two separate genes, 
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located respectively on chromosomes 17 and 3 in man. Both isoforms bind T3 (KD =  
10
-9
 and 10
-10
 respectively) and are involved in mediating gene expression induced by 
thyroid hormone. Moreover additional isoforms are produced by alternative splicing, 
giving rise to TRα1 and TRα2, the latter acting as transcriptional inhibitor, and to 
TRβ1 and TRβ2. TRα1 is expressed mainly in skeletal muscle and brown adipose 
tissue, whereas TRα2 is found more ubiquitously. TRβ1 is concentrated principally in 
brain, liver and kidney, whilst TRβ2 is located exclusively in the anterior pituitary 
gland and in specific hypothalamic areas (Lazar MA, Chin WW, 1990).  
The mechanism that leads to transcription of the genes under thyroid hormone control 
is complex, and a comprehensive description is out of the aims of this thesis. Anyway 
it is important to underline some key aspects of this process. First of all, TRs bind to 
TREs as monomers, homodimers, but also as heterodimers with another important 
class of nuclear receptors, i.e. Retinoid X Receptors (RXRs). RXRs bind 9-cis-retinoic 
acid with high affinity, and form homodimers with Retinoid Acid Receptors (RARs), 
Vit. D Receptors (VDRs) and Peroxisome Proliferator Activated Proteins (PPARs) 
(Glass CK, 1994). This characteristic is important because in this way the amount of 
target genes that can be regulated by T3 is largely increased, considering that 
heterodimers binds to TREs at different sites and with different orientation with 
respect to homodimers (Glass CK, 1994).  
The best model known until now describing the transcriptional activation induced by 
thyroid hormones states that T3 binding to its own nuclear receptor is able to remove a 
transcriptional block imposed by a co-repressor complex located on TRE. A lot of co-
repressor and co-activator proteins have been identified to date, which probably widen 
the range of tissue specificity of the hormonal action (Yen PM et al., 2001). 
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Figure 10  Thyroid hormone: schematic representation of genomic effects. 
 
Nongenomic Effects  
Until three decades ago the vast majority of scientific community was convinced that 
the only way by which thyroid hormones were able to trigger biological effects was 
through transcriptional activation of specific genes, i.e. through a genomic way. 
Starting from the early ‘80s new ideas emerged from the work of several researchers, 
which introduce the concept that thyroid hormones could induce several important 
responses also without directly affecting gene expression, in the so-called nongenomic 
way. Typically these effects are characterised by rapid onset (seconds or minutes), and 
direct interaction of thyroid hormones, both T3 and T4, with plasma membrane proteins 
and/or specific receptors, resulting in allosteric activations and induction of cell 
signaling pathways. Some striking examples are represented by the direct stimulation 
by T3 of human Ca
2+
-ATPase activity in vitro (Davis FB et al., 1983) and 2-
deoxyglucose uptake in rat thymocytes in vitro (Segal J, Ingbar SH, 1981), but several 
others have been described to date. More recently specific effects on ionic fluxes 
through the cell membrane have been reported, as for activation of inward rectifier 
potassium channels currents (Sakaguchi Y et al., 1996), Na
+
/H
+
 antiport (Incerpi S et 
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al., 1999) and Na
+
 and Ca
2+
 currents (Wang YG et al., 2003). Typically these actions 
show a time of onset that ranges between 30 sec to 20 min after hormonal stimulation 
and are observed using concentrations included in the interval 1 nM to 10 nM (Davis 
PJ et al., 2005).  
Some specific biological actions have been discovered for T4 as well, especially for 
what concerns several signaling pathways. For example induction of tyrosine 
phosphorylation and consequent translocation inside the nucleus of STAT3 
transcription factor has been observed and shown to be dependent on PKC, MAPK and 
Raf-1 activation. Moreover a stimulation of interaction between MAPK and TRβ1 
leading to phosphorylation of this receptor has been reported, which has been shown to 
be phosphorylated by p38 MAPK as well (Yen PM, 2001). Other reports have assessed 
the role of T4 in the activation of PLC, leading to DAG production and PKC activation 
(Kavok N et al., 2001). 
All these observations could suggest the existence of a membrane receptor for thyroid 
hormone mediating these effects, and, in fact, a high affinity binding-site has been 
identified on integrin αVβ3 in a fibroblast cell line (Bergh JJ et al., 2005). Since that 
discovery several other papers have reported and described biological effects due to 
the interaction with this integrin (Scarlett A et al., 2008; Yalcin M et al., 2010). 
Interestingly, two recent papers suggested that thyroid hormones, and in particular T3, 
may exert their effects through a novel nongenomic way, which is mediated by a 
cytoplasmic TRβ1 and finally leads to Akt activation (Verga Falzacappa C et al., 2007; 
Verga Falzacappa C et al., 2009). 
In Figure 11 are represented several nongenomic effects triggered by T4, T3 and rT3, 
which lead to the activation of specific signaling pathways. 
27 
 
 
Figure 11  Thyroid hormone: schematic representation of nongenomic effects. 
 
2.5 Diiodothyronines 
Until two decades ago diiodothyronines, 3,5-diiodothyronine (3,5-T2) and 3,3’-
diiodothyronine (3,3’-T2), were considered only a product of catabolism of thyroid 
hormone, without any significant biological effect. But from the mid ‘90s several 
reports began to describe some metabolic actions at the mitochondrial level, these 
molecules being able to rapidly stimulate oxidative rate in rat liver (Lanni A et al., 
1992), by binding and stimulating activity of cytochrome c oxidase, as shown in rat 
hepatocytes in vitro (Lanni A et al., 1994), and confirmed on isolated enzyme as well 
(Goglia F et al., 1994). Moreover a calorigenic effect of both diiodothyronines was 
found to exist in rats in vivo (Lanni A et al., 1996). Indeed it was later demonstrated 
that 3,5-T2 is able to bind to subunit Va of cytochrome c oxidase, completely 
abolishing allosteric inhibition, which usually takes places when [ATP]/[ADP] ratio is 
NONGENOMIC ACTIONS of thyroid hormone that are initiated at the plasma membrane receptor 
on INTEGRIN αvβ3 or in CYTOPLASM.
Cheng S et al. Endocrine Reviews 2010;31:139-170
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high (Arnold S et al., 1998). Recently a direct role of 3,5-T2 in increasing the activity 
of glucose-6-P-dehydrogenase has been assessed in rat (Lombardi A et al., 2000), 
supporting the idea of a biologically active molecule.  
It is interesting to underline that no other physiological effects have been described to 
date for diiodothyronines, so they do not show most of the well-known effect of 
thyroid hormone described above. Only one report demonstrates that 3,5-T2 displays 
some selective thyromimetic effects in vivo and in vitro, being able to suppress TSH 
secretion, even if 50% less with respect to thyroid hormone (Ball SG et al., 1997). 
Moreover no receptors have been identified until now for diiodothyronines, nor 
nuclear, cytoplasmic, or plasma membrane ones. Three cytoplasmic proteins able to 
bind 3,5-T2 have been identified in rat liver, but no insights about the role played by 
these proteins have been proposed (Moreno M et al., 2003).   
 
3. NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) 
3.1 General features 
Non-Alcoholic Fatty Liver Disease (NAFLD) is nowadays considered one of the most 
considerable pathologic conditions affecting the liver especially in western world, with 
the higher prevalence observed in United States of America, United Kingdom and 
north of Europe. Recent reports suggest that about 15% to 20% of population from 
different countries could be affected, with an increasing incidence of people at risk to 
develop this pathology (Anderson N, Borlak J, 2008). The frequency is much higher in 
obese population, for which epidemiological studies report percentages that ranges 
from 57.5% to 74% (Browning JD et al., 2004). NAFLD has been described in 
children as well, with 2.6% occurrence in non-obese subjects, which rises to 22.5% in 
obese ones (Angulo P, 2002). 
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From a clinical point of view, NAFLD can be diagnosed because usually patients show 
the same typical manifestations observed in Alcoholic Liver Disease (ALD), but 
without any excessive consumption of alcoholic beverages. According to some authors 
the amount of alcohol consumed should be lower than 20 g for women and 30 g for 
men to be in presence of NAFLD (Bellentani S et al., 1997).  
For what concerns the diagnostic analysis that can be employed in NAFLD 
assessment, no one of the most common laboratory tests can provide a clear and 
definitive indication of this pathology, liver biopsy being the only instrument with 
which is possible to obtain a well-defined evidence of the presence of this condition 
(Angulo P, 2002). Several risk factors and clinical manifestations can anyway provide 
some useful indications about the possible presence of NAFLD. It has been reported 
that hyperlipidemia, obesity and type II diabetes are recurrently observed in patients 
with NAFLD. For example obese population (BMI≥30) has been found to have a 
higher incidence of a factor of about 5 with respect to non-obese people (Bellentani S 
et al., 2000). Moreover, a positive correlation between truncal obesity and NAFLD has 
been reported also in patients with regular BMI (Ruderman N et al., 1998). In about 
half of patients presenting hyperlipidemia analysed in one clinical study the presence 
of NAFLD was subsequently reported, and the same study established that 
hypertriglyceridemia is a more dangerous risk factor if compared with 
hypercholesterolemia (Assy N et al., 2000). About the clinical manifestations of 
NAFLD, it is important to underline that most people affected have no evident signs of 
the pathology, with the exception of a sense of fullness and/or mild ache on the right 
side of the upper part of abdomen, together with tiredness and hepatomegaly   Some 
laboratory analysis can be useful to assess if a person is affected or not by NAFLD, 
such as serum levels of aminotransferase, alkaline phosphatase, γ-glutamyltransferase. 
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Aspartate aminotransferase and alanine aminotransferase levels are often higher than 
normal in NAFLD patients, as well as that of alkaline phosphatase and γ-
glutamyltransferase, even if to a lesser extent with respect to ALD. Several other 
parameters are subjected to variations when in presence of NAFLD, such as elevated 
serum ferritin levels. Hypoalbuminemia, hyperbilirubinemia and a prolonged 
prothrombin time are often present when NAFLD is in the cirrhotic phase (Angulo P, 
2002). Imaging techniques are employed as well in the diagnosis of NAFLD and may 
represent a valuable tool, with particular reference to ultrasonography, computed 
tomographic (CT) scanning, and magnetic resonance imaging and spectroscopy. 
Ultrasonography has been reported to have a very high sensitivity and specificity in 
identifying steatosis (above 90%), and fibrosis (above 85%) (Joseph AE et al., 1991). 
CT scanning and magnetic resonance imaging can be used in the assessment of fat 
infiltration inside the liver parenchyma, the first being eligible when steatosis is 
diffuse, which is the predominant condition in NAFLD, the second being more 
suitable when infrequently happens that steatosis has a focal pattern. Finally, magnetic 
resonance spectroscopy is commonly used to evaluate the amount of fat infiltrate 
inside the liver parenchyma (Angulo P, 2002).  
From an histological point of view, the typical features observed after a liver biopsy, 
which characterise a liver as a NAFLD liver are steatosis, hepatocyte ballooning, 
glycogen nuclei, mixed inflammatory-cell infiltration, Mallory’s hyaline, cell necrosis 
and fibrosis (Angulo P, 2002). The two following pictures below clearly illustrate 
some of the most typifying features of NAFLD. In Figure 12 [haematoxylin and eosin 
– 200X] is evident the presence of a macrovesicular steatosis, even if in some 
hepatocytes is possible to find both macro- and microvesicular one. The fat infiltrate 
may be found prevalently inside acinar zone 3 when the amount is not so abundant, but 
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increasing quantities of fat led to a more diffuse pattern of distribution. Hepatocyte 
ballooning is visible as well, consisting in a degeneration of the hepatocyte determined 
by an accumulation of intracellular fluid, which induces cell swelling that 
characteristically occurs in zone 3 close to steatotic hepatocytes. In this photo is also 
possible to see Mallory’s hyaline bodies inside the hepatocytes undergoing ballooning 
degeneration in zone 3. These bodies are frequently (≈50%) observed in adult people 
affected by NAFLD but not specific, being present in ALD or other liver pathologic 
conditions as well. Clearly distinguishable is also the inflammatory infiltrate that 
usually consists of lymphocytes and neutrophils, and is localised in zone 3. It is 
interesting to underline that usually in adults the inflammatory infiltrate does not 
localise in portal tracts, whereas in children this is the typical pattern of infiltration. 
Furthermore in children Mallory’s hyaline is usually very scarce or not present 
(Kleiner DE et al., 2005).                                                      
 
Figure 12  NAFLD: macrovesicular steatosis, inflammatory infiltrate, Mallory’s hyaline and hepatocyte 
ballooning (from Angulo P, 2002). 
 
Figure 13 [Masson’s trichrome – 200X], illustrates a clear example of fibrotic liver, in 
which are evident the three typical patterns of fibrosis, i.e. perivenular, pericellular and 
perisinusoidal in zone 3. It is useful to highlight that in NAFLD as well as in ALD, 
collagen is put down initially in the pericellular space around the central vein and in 
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the perisinusoidal region inside the zone 3. Moreover in several regions it is possible to 
observe a typical pattern in collagen deposits, the so-called “chicken-wire” fibrosis. 
Together considered these features can be helpful to distinguish NAFLD- and ALD-
induced fibrosis to a fibrosis provoked by other liver diseases, in which collagen 
deposition typically begins in the portal region (Angulo P et al., 2007).                       
 
Figure 13  NAFLD: perivenular, pericellular and perisinusoidal fibrosis in zone 3 (from Angulo P, 
2002). 
 
In 1999 Brunt EM and co-workers (Brunt EM et al., 1999), proposed a valuable 
classification of NAFLD, according to degree of severity and localisation of steatosis, 
inflammation and fibrosis observed.          
Grading for steatosis 
Grade 1→<33% of hepatocytes affected 
Grade 2→33% to 66% of hepatocytes affected 
Grade 3→>66% of hepatocytes affected 
Grading for steatohepatitis 
Grade 1→mild 
-Steatosis: predominantly macrovesicular, involves up to 66% of lobules 
-Ballooning: occasionally observed; zone 3 hepatocytes 
-Lobular inflammation: scattered and mild acute inflammation (polymorphonuclear 
  cells) and occasional chronic inflammation (mononuclear cells) 
-Portal inflammation: none or mild 
Grade 2→moderate 
-Steatosis: any degree; usually mixed macrovesicular and microvesicular 
-Ballooning: obvious and present in zone 3 
-Lobular inflammation: polymorphonuclear cells may be noted in association 
  with ballooned hepatocytes; pericellular fibrosis; mild chronic inflammation may be seen 
-Portal inflammation: mild to moderate 
Grade 3→severe 
-Steatosis: typically involves >66% of lobules (panacinar); commonly mixed steatosis 
-Ballooning: predominantly zone 3; marked 
-Lobular inflammation: scattered acute and chronic inflammation; polymorphonuclear 
  cells may be concentrated in zone 3 areas of ballooning and perisinusoidal fibrosis 
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-Portal inflammation: mild to moderate 
Staging for fibrosis 
Stage 1→zone 3 perivenular, perisinusoidal, or pericellular fibrosis; focal or extensive 
Stage 2→as above, with focal or extensive periportal fibrosis 
Stage 3→bridging fibrosis, focal or extensive 
Stage 4→cirrhosis 
 
3.2 Pathogenesis 
The pathological mechanisms that induce the development of NAFLD are so far not 
completely clarified and still matter of debate, even if some key factors seem to be 
elucidated. One fundamental condition that has to be satisfied is a significant 
accumulation of lipids inside the hepatocyte, principally as triglycerides. Several 
theories have been proposed to date, but now most researchers believe that the first 
step required for onset of NAFLD is certainly insulin resistance, according to what 
hypothesised by Day CP and James OFW in 1998. Insulin resistance, in turn, would 
lead to fat accumulation, and hence to steatosis, probably inducing modifications in the 
uptake, synthesis, oxidation or export of lipids, as shown in the following figure 
(Angulo P, 2002).      
 
 
Figure 14  NAFLD: fatty acid metabolism in a normal hepatocyte (from Angulo P, 2002). 
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Onset of insulin resistance is indeed a complex topic to deal with, even if until now 
some points have been clarified. Several molecules, as reported in figure 15, can block 
insulin action. Once induced an insulin resistance condition, two main events are 
thought to be responsible for progression to a steatotic state: hyperinsulinemia and 
increase in lipolysis at the adipocyte level. At the hepatocyte level, hyperinsulinemia 
leads to an enhancement of glycolytic pathway, resulting in an increased synthesis of 
fatty acids. Moreover, the concomitant decrease in apolipoprotein B-100 (ApoB-100) 
synthesis has the final effect to raise the triglycerides content inside the cell. Increased 
lipolysis at the adipose tissue level determines the increase of the haematic 
concentration of fatty acids, which in turn are up taken by the liver. Such excess of 
fatty acids induces two parallel effects: an overwork of mitochondrial β-oxidation that 
leads to accumulation of fatty acids themselves, and a stimulation of synthesis of 
cytochrome P-450 2E1 and 4A that in turn are able to trigger the production of 
Reactive Oxygen Species (ROS), responsible for an extensive lipid peroxidation of 
cell membranes (Weltman MD et al., 1998; Leclercq IA et al., 2000).  
 
Figure 15  NAFLD: metabolic pathways in an insulin resistant hepatocyte (from Angulo P, 2002). 
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Another aetiology that has been proposed for onset of NAFLD involves deregulations 
of fatty acids oxidation pathways at the hepatocyte level. As illustrated in figure 16, 
the increased amount of fatty acids present in the insulin-resistant hepatocyte may 
result in three principal outcomes. First of all microsomal ω-oxidation is increased, 
leading to production of dicarboxylic acids, which are supposed to be cytotoxic and 
are targeted to peroxisomal β-oxidation. Peroxisomal β-oxidation is thought to have an 
extremely important role in the pathogenesis of NAFLD, if considered that the absence 
of peroxisomal fatty acyl-CoA oxidase has been shown to be responsible for the 
induction of extensive microvesicular steatosis and steatohepatitis as well. 
Furthermore if this enzyme does not work, much of the acyl-CoA produced by 
peroxisomes is no further processed and acts as a PPAR-α ligand, hyperactivating it, 
and inducing as a consequence the up-regulation of PPAR-α–controlled genes, as those 
involved in mitochondrial, peroxisomal and microsomal enzyme systems (Fan CY et 
al., 1998). An additional gene that has been proved to be under PPAR-α influence and 
that can be found in liver from NAFLD patients is uncoupling protein-2 (UCP-2). Its 
part in NAFLD progression it is not well defined, but some authors have proposed a 
role in raising the susceptibility of the fatty hepatocyte to secondary hits, such as TNF-
α or endotoxins (Chavin KD et al., 1999).     
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Figure 16  NAFLD: metabolic pathways in an insulin resistant hepatocyte, with particular reference to 
microsomal ω-oxidation and peroxisomal β-oxidation (from Angulo P, 2002). 
 
According to what discovered until now, the progression from simple steatosis to 
steatohepatitis and eventually cirrhosis and fibrosis is largely due to raised intrahepatic 
level of reactive oxygen species (ROS), produced at the mitochondrial level as a 
consequence of the surplus of fatty acids. ROS in turn are able to trigger at least three 
different processes: lipid peroxidation, cytokine induction and Fas ligand (FasL) 
expression. The two main products derived from lipid peroxidation are 
malondialdehyde (MDA) and 4-hydroxynonenal (HNE) that cause several deleterious 
effects at the cellular level. Primarily they can induce cell death and are as well 
thought to be responsible for the formation of Mallory’s hyaline, through protein cross 
linking (Zatloukal K et al., 1991). Secondarily, it has been shown that they are able to 
promote collagen deposition by activating hepatic stellate cells (HSC) (Leonarduzzi G 
et al., 1997). Thirdly, HNE behaves as a proinflammatory agent, showing a 
chemotactic action towards neutrophils (Curzio M, 1985).  
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For what concerns cytokine induction, there are several evidences reporting that ROS 
have a role in promoting the formation of TNF-α, TGF-β, and interleukin-8 (IL-8). 
TNF-α and TGF-β make caspase to be activated (Higuchi M et al., 1997; Inayat-
Hussain SH et al., 1997), whereas TGF-β alone works as a cofactor, together with 
MDA and HNE, in the process of building up Mallory’s hyaline, doing so by 
stimulating collagen production by HSC (Leonarduzzi G et al., 1997) and activating 
tissue transglutaminase, which cause cytoskeletal proteins to cross-link (Angulo P, 
2002). Finally IL-8 is well known as a powerful chemoattractant molecule for 
neutrophils (Yoshimura T et al., 1987). 
Several cooperating factors have been shown to trigger FasL expression at the 
hepatocyte level, which together led to an important increase in ROS concentration, by 
means of a sort of positive feedback. Two aspects need to be noticed: first, ROS-
induced TNF-α inhibits action of respiratory chain at the mitochondrial level 
(Lancaster JR Jr et al., 1989), second, ROS reduce the antioxidant pool inside the 
hepatocyte, in this way causing more ROS to be produced (Sastre J et al., 1989). All 
these ROS has as a consequence the expression of FasL (Hug H et al., 1997), which 
can interact with Fas molecule present in the neighbouring hepatocytes, with the effect 
of a diffuse cell death. 
Mitochondria seem to play a central role in the pathogenesis of NAFLD, if considered 
that in non-affected population and in the vast majority of patients with simple 
steatosis, this organelle show no significant abnormalities, but ultrastructural injuries, 
as linear crystalline inclusions inside megamitochondria, can be evidenced in patients 
with steatohepatitis (Sanyal AJ et al., 2001). Additionally, patients with steatohepatitis 
show alterations in liver ATP homeostasis, characterised by slowed rates of ATP 
synthesis, resulting in a severe ATP depletion (Cortez-Pinto H et al., 1999). As 
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explained in the previous paragraph this effect can be induced by an increased 
oxidative as well as inflammatory stress.                         
 
 
 
Figure 17  NAFLD: metabolic pathways in a steatotic hepatocyte (from Angulo P, 2002). 
 
It is thus possible to state, according to Day CP and James OFW (Day CP, James 
OFW, 1998), that NAFLD pathogenesis can be described as a two-steps or “two-hits” 
process, the first being represented by onset of insulin resistance, which induces fat 
overload at the hepatic level. Secondarily, the oxidative stress generated by excess of 
lipids is able to trigger a series of linked events as lipid peroxidation, cytokine and 
FasL induction, which together can cooperate to induce steatohepatitis and finally 
fibrosis.    
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3.3 Insights on Insulin Resistance (IR) 
Diabetes Mellitus (DM) can certainly be considered one of the principal metabolic 
diseases in the modern age. It has been estimated that actually more that 140 million 
people are affected worldwide and that this number is expected to double by 2025 
(Zimmet P et al., 2001). As an outstanding example, it is useful to consider that in 
USA, some estimates report a probable number of 16 million affected subjects, with 
about 54000 deaths/year due to diabetes-related causes (Narayan KM et al., 2003).   
Actually scientists and physicians agree on the assumption that DM can be better 
described classifying it in two major categories: Type I DM, in which pancreatic β-
cells are destroyed due to an autoimmune reaction, and Type II DM, which is thought 
to be provoked by a peripheral resistance to insulin action, together with an 
insufficient secretion by pancreatic β-cells, the so-called “relative insulin deficiency”. 
From an epidemiological point of view, Type I DM accounts for approximately 10% 
of all patients, whereas the remaining part should be included in Type II DM. A small 
number of cases, about 5%, is due to other causes, as for example, some monogenic 
forms such as Maturity-Onset Diabetes of the Young (MODY), Mitochondrial 
Diabetes, or several forms provoked by insulin gene or insulin receptor mutations. In 
addition other possible causes should be mentioned, such as exocrine pancreas defects, 
some endocrinopathies, such as Cushing syndrome, infections with cytomegalovirus 
and Coxsackie virus B, and several drugs (Report of the Expert Committee on the 
Diagnosis and Classification of Diabetes Mellitus, 2002).            
3.3.1 Insulin action: normal and pathological  
In normal, non-affected people, insulin plays an essential role in the process of 
maintenance and regulation of glucose homeostasis, together with its companion 
hormone, glucagon, through the well-known mechanism. 
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At the level of β cells of the pancreatic islets, insulin is synthesized as preproinsulin in 
the rough endoplasmic reticulum (RER), and directed to Golgi apparatus, where the 
mature insulin is produced and stored in secretory granules, together with C-peptide. 
When the haematic levels of glucose rise as a consequence of a meal, pancreatic β 
cells uptake glucose itself through GLUT-2 transporter. Glucose catabolism inside the 
cells leads to increased production of ATP that results in higher values of the 
cytoplasmic ATP/ADP ratio, which in turn are able to inhibit the ATP-sensitive K
+
-
channel present on plasma membrane, with depolarisation and Ca
2+
 influx through 
voltage-dependent channels. Higher [Ca
2+] induces insulin release from β cells 
granules, the so-called immediate release of insulin. When the stimulus continues to be 
present, the β cell begins to actively synthesise insulin, and this kind of response is 
usually prolonged in time. 
As mentioned before, insulin is fundamentally a hormone that exerts anabolic 
functions, being responsible for augmenting the uptake of glucose at the level of 
adipose tissue, striated and myocardial muscle, and liver.      
Figure 18 summarises the physiological effects of insulin in the three aforementioned 
organs, in a normal condition, in fed and fasting states, and when Type II DM is 
present. When the system works properly, insulin secretion is stimulated after a 
carbohydrate (CHO in the figure) intake, as discussed before. At the level of skeletal 
muscle, glucose uptake is increased as well as glycogen synthesis, similarly to what 
happens in the liver, where glycogen synthesis and de novo lipogenesis are stimulated, 
whereas gluconeogenesis is inhibited. Lipogenesis is stimulated in white adipose tissue 
(WAT) as well, together with a down regulation of lipolysis. The primary event 
leading to insulin resistance and Type II DM development seems to be the ectopic 
intramyocellular lipid (IMCL) accumulation, which results in a blockage of glucose 
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uptake and glycogen synthesis. Secondarily, the excess of glucose present in the 
bloodstream after a meal is then directed to the liver, where contributes to increase 
intrahepatic triglycerides content, promoting a steatotic condition. Moreover, in the 
fasted state lipolysis is largely stimulated in WAT, and the surplus of circulating fatty 
acids is re-esterified in the liver, further contributing to augment steatosis (Samuel VT, 
Shulman GI, 2012).                        
 
 
 
Figure 18  IR: schematic representation of insulin effect in normal and T2DM conditions (from Samuel 
VT, Shulman GI, 2012). 
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3.3.2 Insulin resistance 
Onset of insulin resistance is certainly one of the most intriguing and challenging 
topics to deal with in cellular and molecular biology, considering that many cellular 
processes involved have been identified until now, but that many others remain 
obscure so far. At least two aspects seem to play a central role in contributing to 
insulin resistance development: ectopic lipid accumulation at skeletal muscle and liver 
level, as mentioned before, and the Unfolded Protein Response (UPR) or endoplasmic 
reticulum stress, whereas not completely clarified is which part inflammation has in 
the overall process. 
For what concerns lipid accumulation, it is now completely defined that in both 
skeletal muscle and liver, this is the first step that is able to trigger insulin resistance. 
The mechanism proposed is quite similar in both tissues, as depicted in the next two 
pictures, representing skeletal muscle and liver respectively (Samuel VT et al., 2010).      
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Figure 19  IR: schematic representation of signaling and metabolic pathways involved in onset of IR in 
skeletal muscle (from Samuel VT, Shulman GI, 2012). 
 
 
In skeletal muscle, insulin binding to its own receptor (IR) present in the plasma 
membrane leads to activation of its tyrosine kinase activity, which result in 
phosphorylation of Insulin Receptor Substrate proteins 1 and 2 (IRS1/2). This event in 
turn is able to activate Akt2 by several steps that will be analysed deeper in the next 
paragraph. Activated Akt2 determines the translocation of GLUT4-containing storage 
vesicles (GSVs) to the plasma membrane and activation of glycogen synthase (GS). 
Several distinct but as well as overlapping biochemical deregulations can perturb this 
pathway. First of all, it has been shown that lipid accumulation is able to induce an 
increase in diacylglycerol (DAG) content, which is a well-known activator of protein 
kinase C (PKC) family that belongs to AGC super family of serine/threonine kinase. 
Indeed, now PKC family has been sub classified in three distinct groups: conventional 
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PKCs (cPKC: α, βI, βII, γ) that need both DAG and Ca2+ to be activated, novel PKCs 
(nPKC: δ, ε, η, θ) for which only DAG is required, and atypical PKCs (aPKC:  ζ, λ) 
that are not dependent on DAG and/or Ca
2+
.  It has been demonstrated that in skeletal 
muscle raised levels of DAG lead to PKCθ activation, which in turn phosphorylates 
IRS-1 on Ser
1101
, resulting in an inhibition of insulin signaling due to an impairment of 
the physiological Tyr phosphorylation (Li Y et al., 2004). Interestingly, a role in 
insulin resistance onset has been proposed for ceramides, which would be able to 
inhibit Akt2 activation by means of two different mechanisms. First, by activating 
protein phosphatase 2A (PPA2), which directly dephosphorylate Akt2, second by 
blocking the dissociation of the complex PKCζ•Akt2, in this way impairing Akt2 
functionality (Teruel T et al., 2001; Powell DJ et al., 2003). A part in this movie has 
been suggested for inflammatory response as well, with particular attention to TNFα 
signaling. In fact, it has been shown that in obese subjects adipose tissue macrophages 
[ATMs] release TNFα, which in turn, through jun-N-terminal kinase 1 (JNK1) 
activation may block insulin signaling by phosphorylation of IRS1 at Ser
307
 residue 
(Hotamisligil GS et al., 1996; Aguirre V et al., 2002). For what concerns the function 
of UPR in the onset of insulin resistance, it has been assessed that an activation of this 
pathway may lead to an impairment of insulin signaling, even if a clear association 
between these two aspects has not been found yet. In mice it has been observed that a 
high-fat diet is able to induce the UPR, but the same has not been found in humans. 
Interestingly, a possible involvement of UPR in the response of skeletal muscle to 
exercise has recently been reported, through activation of Peroxisome proliferator 
Gamma Coactivator 1α (PGC-1α) and ATF6α, but how this process could be linked to 
insulin sensitivity remains unclear (Samuel VT, Shulman GI, 2012).                               
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Figure 20  IR: schematic representation of signaling and metabolic pathways involved in onset of IR in 
the liver (from Samuel VT, Shulman GI, 2012). 
 
Many aspects just described for skeletal muscle are quite similar in the liver as well, 
even if some differences exist. First of all, different PKCs, through slight dissimilar 
mechanisms, have been found to contribute to the development of insulin resistance, 
with respect to skeletal muscle. PKCε is usually found strictly associated with the IR 
in rats, and an activation of this kinase due to increased levels of DAG is supposed to 
lead to an impairment of IR activity. PKCδ has been reported as well to have a role in 
rat liver, and evidences collected until now permit to conclude that probably this 
kinase may be activated in two distinct ways: the first one classically by DAG, the 
second one being able to respond to the proinflammatory milieu that can arise as a 
consequence of a continuative hyperlipidemia, probably through IL6R or IKK-β. 
Similarly to what described in the skeletal muscle, ceramides induces the activation of 
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PP2A, which in turn dephosphorylates Akt2, impairing its functionality. Moreover 
ceramides are able to block the dissociation of the complex PKCζ•Akt2 that normally 
occurs after insulin stimulation, again impeding Akt2 effects (Teruel T et al., 2001; 
Powell DJ et al., 2003).     
About the role played by UPR, most aspects resemble those observed in skeletal 
muscle, with only minor differences. On this regard, it is interesting to underline the 
role of transcription factor XBP1 (X-box Binding Protein 1), which is thought to exert 
a deleterious part in the onset of insulin resistance, increasing levels of intracellular 
DAG in this way stimulating PKCε activation (Jurczak MJ et al., 2012).       
 
3.4 mTOR: Structure and Functions 
The presence of efficient systems able to regulate and organise all the complex 
pathways involved in metabolic processes is indeed essential for every living 
organism. At the apex of the evolutionary tree, Mammals have developed several 
devices to cope with this matter, and one of most intensively studied in the last years 
as well as in the present days, is certainly the pathway activated by the protein kinase 
mammalian target of rapamycin or mTOR. So far several pathological conditions in 
humans have been shown to be induced by the non proper functioning of mTOR, 
including tumours, neurodegenerative processes, obesity and type II diabetes. For this 
reasons, many research groups worldwide are actually studying this topic, trying to 
find pharmacological approaches useful from a therapeutic point of view (Samuel VT, 
Shulman GI, 2012). 
3.4.1 Structure 
mTOR was originally discovered due to its inhibition operated by rapamycin, also 
named sirolimus, a macrolide synthesised by Streptomyces Hygroscopicus bacteria      
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that owns a typical antiproliferative action. Two studies published in 1993, for the first 
time identified two possible genes mediators of the cytotoxic effect of rapamycin in S. 
cerevisiae, named TOR1 and TOR2 (Cafferkey R et al., 1993; Kunz J et al., 1993). 
Biochemical approaches led rapidly to the characterisation of mTOR, of the 12-kDa 
FK506-binding protein (FKBP12) that is able to bind to rapamycin (Brown EJ et al., 
1994; Sabatini DM et al., 1994; Sabers CJ et al., 1995) and also to the discover of the 
binding site for the complex rapamycin•FKBP12 (Chen J et al., 1995).  
From a biochemical point of view, mTOR can be classified as an atypical Ser/Thr 
protein kinase, included in the broad family of phosphoinositide 3-kinase (PI3K)- 
related kinase. Usually it interacts with different proteins, which confer to mTOR 
peculiar characteristics that define its physiological functions. Depending on which 
proteins mTOR associates with, it forms two different complexes with different roles 
and sensitivity to rapamycin, termed mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2). These two complexes are quite large, and so far six proteins 
have been discovered for mTORC1 and seven for mTORC2, in addition to the 
common catalytic subunit mTOR. Excluding mTOR, four components are shared by 
the two complexes, termed: mammalian lethal with sec-13 protein 8 (mLST8 or GβL), 
DEP domain containing mTOR-interacting protein (DEPTOR) and the Tti1/Tel2 
complex. Specific proteins characterise the two assemblies, i.e. regulatory-associated 
protein of mTOR (raptor) and proline-rich Akt substrate 40 kDa (PRAS40) for 
mTORC1, and rapamycin-insensitive companion of mTOR (rictor), mammalian-stress 
activated map kinase-interacting protein (mSin1) and protein observed with rictor 1 
and 2 (protor1/2) for mTORC2. The two aforementioned complexes greatly differ for 
the sensitivity to rapamycin, mTORC1 being strongly inhibited by acute treatment, 
differently to mTORC2, which seems to be targeted only by chronic exposures that 
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probably disassembly its structure. The biochemical and structural basis for this effect 
are until now not completely clear, even if it has been proposed a destabilising action 
on the complex as well as an allosteric inhibition of the kinase domain (Laplante M, 
Sabatini DM, 2012).        
 
Figure 21  mTOR: schematic representation of mTORC1 and mTORC2 complexes (from Laplante M, 
Sabatini DM, 2012). 
 
3.4.2 mTORC1 & mTORC2: upstream 
From what depicted in Figure 21, it is clearly understandable that at the present time 
there is more information about mTORC1 with respect mTORC2, even though now 
many efforts are concentrated on mTORC2.  
Several factors connected to energetic status of the cell have been shown to be 
responsible for the activation of mTORC1, i.e. oxygen, amino acids, energy levels as 
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well as growth factors, having as outcome the control of some of the most important 
cellular processes, as macromolecule biosynthesis, for instance lipid and proteins, cell 
cycle progression, autophagy, cell growth and metabolism.  
For what concerns mTORC2, it is known that it is activated by growth factors, and that 
it regulates cell survival, metabolism and cytoskeletal organisation.          
 
 
 
Figure 22  mTOR: schematic representation of signaling and metabolic pathways regulated by 
mTORC1 and mTORC2 complexes (from Laplante M, Sabatini DM, 2012). 
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Figure 22 summarises the state of art of what is known about mTORC1- and 
mTORC2-activated signaling pathways and the principal processes regulated by these 
two complexes. 
A central role in the regulation of mTORC1 activity is undoubtedly played by TSC1/2 
complex, an heterodimer of two distinct subunits, termed TSC1 (Tuberous SClerosis 1 
or hamartin) and TSC2 (Tuberous SClerosis 2 or tuberin). TSC1/2 owns a GTPase-
activating protein (GAP) activity, and it is able to inactivate Rheb (Ras homolog 
enriched in brain) GTPase favouring the formation of the GDP-bound form, in this 
way permitting a negative regulation of the mTORC1 activation. On TSC1/2 converge 
almost all the external stimuli that activate or inhibit activity of mTORC1, with the 
important exception of amino acids, which seem to act in a TSC1/2-independent 
manner. Among the best characterised pathways that can induce mTORC1 regulation 
through TSC1/2 at least five should be mentioned: growth factors, proinflammatory 
cytokines, Wnt pathway, together with hypoxia and DNA damage. Growth factors, 
insulin and insulin-like growth factor 1 (IGF1) being paradigmatic, classically activate 
Ras and PI3K signaling, resulting in the activation of extracellular-signal-regulated 
kinase 1/2 (ERK1/2), protein kinase B (Akt/PKB), and ribosomal S6 kinase (RSK1), 
which inactivate the TSC1/2 complex by phosphorylation, inducing as a consequence 
mTORC1 activation (Inoki K et al., 2002; Ma L et al., 2005). Interestingly Akt has 
been shown to activate mTORC1 directly, phosphorylating and inducing the 
dissociation of the PRAS40 inhibitory subunit from the complex (Vander Haar E et al., 
2007). Proinflammatory cytokines, as for example TNFα, similarly stimulate 
mTORC1 by inactivation of TSC1/2, mediated by IKKβ phosphorylation of TSC1 
(Lee DF et al., 2007). Wnt pathway, on the other hand, operates through inhibition of 
glycogen synthase kinase 3β (GSK3- β), which usually phosphorylates TSC2, 
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promoting the activity of the complex (Inoki K et al., 2006). As mentioned above, 
cellular stresses as hypoxia and DNA damage can affect mTORC1 functionality. 
Hypoxia and energy deficit inside the cell are sensed by adenosine monophosphate-
activated protein kinase (AMPK), which in turn is capable of phosphorylating TSC2, 
inhibiting mTORC1, or similarly to Akt, can directly phosphorylate raptor subunit, 
inducing an allosteric inhibition of mTORC1. An emerging role in this picture is being 
assessed for transcriptional regulation of DNA damage response 1 (REDD1), which 
has been demonstrated to be able to stimulate TSC2 after activation by hypoxia, as 
well as by p53. p53 is also essential in the response to DNA damage, considering that 
a p53-dependent transcription mechanism induces the expression of Tsc2 and 
phosphatase and tensin homolog deleted on chromosome 10 (Pten) genes, with the 
resulting overall down regulation of the signaling pathway (Feng Z et al., 2005).  
For what concerns the mechanism by which amino acids are able to activate mTORC1, 
several progresses have been made, even if the overall process is still very far to be 
completely clarified. At present it seems clear that all amino acids, but especially 
leucine and arginine, are necessary to activate mTORC1, even in presence of other 
stimuli, as growth factors, and that the mechanism is TSC1/2-independent. Recently a 
model has been proposed that involves Rag GTPases as the principal mediators of 
regulation of mTORC1 activity by amino acids. In Mammals exists four types of Rag 
proteins, RagA to RagD, which associate obligatory to form RagA/B and RagC/D 
heterodimers, with opposite nucleotide binding properties, that means that when one 
heterodimer is bound to GTP the other one is bound to GDP. In this context, amino 
acids stimulate RagA/B binding to GTP, permitting the interaction with raptor that 
determines the translocation of mTORC1 to the lysosomal surface, where Rag GTPase 
interacts with a multisubunit complex called Ragulator, necessary for mTORC1  
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activation (Sancak Y et al., 2008;  Sancak Y et al., 2010). Once on the lysosomal 
surface, mTORC1 is probably activated thanks to the action of Rheb GTPase, even 
though more investigations need to verify this hypothesis (Laplante M, Sabatini DM, 
2012). Interestingly, a recent paper suggests that amino acids, by accumulating inside 
the lysosomal lumen should be able to activate vacuolar H
+
-adenosine triphosphate 
ATPase (v-ATPase), which in an unknown way would activate Ragulator and Rag 
GTPase (Zoncu R et al., 2011). 
Less is known about mTORC2 activation if compared to mTORC1, even if some 
recent papers are shedding some light on this topic. First of all, about the effect of 
rapamycin, mTORC2 differently to mTORC1 is not affected by an acute treatment 
(Jacinto E et al., 2004), even if the situation is probably more complex, considering 
that it has been shown that in many cell types a prolonged treatment with rapamycin 
can interfere in an unknown way with mTORC2 assembly (Sarbassov DD et al., 
2006). For what concerns mTORC2 activation, the mechanism remains at the present 
day quite obscure, being insensitive to stimulation by nutrients but responsive to 
growth factors such as insulin. A possible way of activation has been recently 
proposed, which recognises a direct role of ribosomes that seem to be able to directly 
activate mTORC2, after that insulin, through a PI3K signaling, promotes mTORC2 
association with ribosomes themselves (Zinzalla V et al., 2011). 
3.4.3 mTORC1 & mTORC2: downstream 
Several essential cellular processes have been shown to be under the direct control of 
mTORC1, such as protein and lipid synthesis, energy metabolism, autophagy and 
lysosome biogenesis.  
According to what has been discovered so far, protein synthesis is regulated by 
mTORC1 essentially by phosphorylation of two key proteins, i.e. the S6 kinase 1 
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(S6K1) and the translational regulators eukaryotic translational initiation factor 4E 
(elF4E)-binding protein 1 (4E-BP1). Phosphorylation of S6K1 leads to its activation, 
which finally results thanks to a series of effectors, in an increase of mRNA 
biogenesis, and translational initiation and elongation. Differently phosphorylation of 
4E-BP1 has the result to block its binding to the cap-binding protein elF4E, favouring 
on the other that to elF4F, inducing in this way the formation of the complex necessary 
for the initiation of cap-dependent translation. Two additional factors play a role in this 
process: the regulatory element tripartite motif-containing protein-24 (TIF-1A), which 
upon activation by mTORC1 interacts with RNA Polymerase I (Pol I), stimulating 
ribosomal RNA (rRNA) transcription, and the Pol III repressor Maf1, which is 
inhibited by phosphorylation, allowing the transcription of 5S rRNA and transfer RNA 
(tRNA) (Ma XM, Blenis J, 2009; Kantidakis T et al., 2010). 
The main way by which mTORC1 controls lipid biosynthesis is by inducing the 
expression and increasing the activity of PPARγ, the well-known central regulator of 
lipogenic genes. Importantly, several recent papers have pointed out that mTORC1 can 
regulate sterol regulatory element-binding protein 1/2 (SREBP1/2) activity, positively 
affecting its functions in an until now not well established way, even if a role for 
Lipin-1 has recently been proposed (Laplante M, Sabatini DM, 2009; Peterson TR et 
al., 2011).  
For what concern energetic metabolism, is now well established that mTORC1 is able 
to positively affect transcription and translation of hypoxia inducible factor 1α 
(HIF1α), which positively regulates many genes involved in the glycolytic pathway. 
Several evidences demonstrate a positive role played by mTORC1 on oxidative 
metabolism as well, being able to augment mitochondrial DNA content and the 
expression of the genes of oxidative metabolism, presumably by favouring the 
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association inside the nucleus of PPARγ Coactivator 1α (PGC1α) and the transcription 
factor Ying-Yang 1 (YY1) (Düvel K et al., 2010). 
Anabolic processes and cell growth are also stimulated by mTORC1 indirectly, 
through a negative regulation of autophagy and lysosome biogenesis. The first task is 
achieved in Mammals by means of the direct phosphorylation of the kinase complex 
ULK/Atg13/FIP200 (unc-51-like kinase 1/mammalian autophagy-related gene 
13/focal adhesion kinase family-interacting protein of 200 kDa), whose activity is 
requested to start the autophagy process (Hosokawa N et al., 2009), and through the 
inhibition of the suppressor of autophagy DAP1(death-associated protein 1) (Koren I 
et al., 2010). Likewise mTORC1 inhibits lysosome biogenesis by phosphorylating the 
transcription factor EB (TFEB), in this way blocking its entry inside the nucleus and 
impeding the transcription of many genes that play essential roles for the proper 
functioning of these organelles (Settembre C et al., 2012). 
Two main pathways downstream mTORC2 have been identified to date, both ones 
involving chains of phosphorylation events, but leading to different outcomes. The 
most characterised pathways are those involving Akt and serum- and glucocorticoid-
induced protein kinase 1 (SGK1). mTORC2 directly phosphorylate Akt on the critical 
Ser473 residue, resulting in its full activation (Sarbassov DD et al., 2005), which 
affects several essential cellular processes, such as metabolism, growth and 
proliferation, survival and apoptosis, at level of many tissues, as will explained in 
greater detail in the next paragraph. Anyhow it is possible to say that when mTORC2 
is defective, the consequent lack of Akt functionality results in impaired 
phosphorylation of several key Akt targets, such as forkhead box O1/3A (FoxO1/3A). 
Another important kinase under the direct influence of mTORC2 is SGK1, which 
modulates cell growth and ion transport, and that is able as well to phosphorylate 
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FoxO1/3A on the same residues phosphorylated by Akt, thus introducing an 
interesting double check on FoxO1/3A activity (Garcìa-Martinez JM, Alessi DR, 
2008). Finally it is important to underline the role played by mTORC2 in the activation 
of PKC-α that together with paxillin and Rho and Rac GTPases plays a relevant role in 
the actin cytoskeleton organisation and dynamics (Jacinto E et al., 2004). 
3.4.4 mTORC1 & mTORC2: metabolic functions and tissue-specific roles  
Both mTORC1 and mTORC2 complexes have been shown to exert fundamental 
functions in the regulation of key metabolic processes, in at least four organs, i.e. 
white adipose tissue (WAT), muscle, pancreas (β-cells) and liver. Moreover, recent 
researches have assessed a new, important role in the regulation of energy balance at 
the hypothalamus level (Laplante M, Sabatini DM, 2012).  
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Figure 23  mTOR: schematic representation of signaling and metabolic pathways regulated by 
mTORC1 and mTORC2 complexes in hypothalamus, adipose tissue, muscle, liver and pancreas (from 
Laplante M, Sabatini DM, 2012). 
 
The hypothalamus has been subjected to extensive research efforts, in the attempt to 
find potential pathways involved in the onset of obesity and metabolic unbalances, 
considering that this area of the brain is of pivotal importance in the processes of 
integration of signals brought by nutrient molecules present in the bloodstream, such 
as lipids, amino acids and proteins, and by hormones such as insulin and leptin 
(Schwartz MW, Porte Jr D, 2005). One specific area of hypothalamus, the arcuate 
nucleus (ARC), has been shown to be particularly important in this context, and to 
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express mTORC1, whose activation induced by leucine or leptin is able to reduce food 
intake, with a mechanism that probably through S6K1 activation, leads to a reduced 
expression of neuropeptide Y (NPY) and agouti-related peptide (AgRP). In pathogenic 
conditions, such as nutrients overload and obesity, mTORC1 is no more activated by 
leptin, inducing a condition of hyperphagia, opening the mind to speculations about 
the possible existence of genetic predispositions eventually responsible for an altered 
control of food intake (Cota D, 2009).   
At WAT level, mTORC1 plays a key role in the regulation of adipogenesis, as 
demonstrated by the observation that when inactivated, this process is completely 
blocked, and when overactive adipogenesis is strongly activated (Laplante M, Sabatini 
DM, 2009). Two proteins under mTORC1 control are central in the development of 
adipose tissue, S6K1 that direct the step from embryonic stem cells to adipogenic 
progenitors through the regulation of early adipogenic transcription factors, and 4E-
BPs under whose translational control is PPARγ, which determines the terminal 
differentiation process (Carnevalli LS et al., 2010). The obesity condition is usually 
associated with high circulating levels of nutrients, insulin and proinflammatory 
cytokines, which are able to stimulate mTORC1 activity, with the final result of further 
increasing adipose mass, and also contributing to insulin resistance onset, through an 
S6K1-mediated block of insulin signaling (Um SH et al., 2004). An increased 
activation of mTORC1 can also result in a high rate of protein synthesis that can lead 
to an augmented ER stress and UPR, processes known to be able to trigger or 
exacerbate an insulin resistance condition (Ozcan U et al., 2008; Hotamisligil GS, 
2010). Interestingly, mTORC2 as well seems to give a positive contribution to the 
correct metabolic homeostasis of WAT and to maintain the proper lipid profile, as 
demonstrated by the fact that mTORC2 adipose-specific ablation results in a regular 
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adipose tissue mass, but the lack of Akt activity leads to an increased lipolysis and to a 
consequent augment of free fatty acids (FFA) in the bloodstream (Kumar A et al., 
2010).    
For what concerns muscle, an interesting recent topic is that concerning the 
relationship between exercise and thus mechanical contraction, and mTORC1. In fact, 
in an unknown way, these kind of mechanical stimuli result in mTORC1 activation, 
with a consequent increase of protein synthesis, which finally results in muscle 
hypertrophy (Philp A et al., 2011).  It has been also shown that mTORC1 is involved 
in the increase of oxidative metabolism by inducing the expression of PGC1-α, and 
that the normal feedback loop that regulate IRS1 activity is strongly reduced in the 
absence of mTORC1, which results in an enhanced Akt activation and glycogen 
accumulation. Similarly, elevated levels of mTORC1 activation, induced by high fat 
feeding and obesity, are able to inhibit insulin signaling in a S6K1-dependent manner, 
with the final result of a reduced glucose uptake, contributing to systemic insulin 
resistance (Um SH et al., 2004). Paradoxically, when mTORC1 is activated as a 
consequence of obesity the effect on muscle mass is deleterious, and a reduction is 
observed, probably mediated by an increased expression of ubiquitin ligases by FoxO1 
(Wang X et al., 2006). Moreover, high-fat diet, obesity and type 2 diabetes, conditions 
that usually results in high levels of mTORC1 activation, have as a typical outcome an 
impaired mitochondrial biogenesis and functionality (Sparks LM et al., 2005). A 
possible explanation for this apparent contradiction is that probably other signaling 
pathways, different from those regulated by mTORC1 control these processes 
(Laplante M, Sabatini DM, 2012). mTORC2 seems to have no effect on muscle mass, 
but an inhibition results in a diminution of glucose uptake and therefore in a mild 
systemic glucose intolerance (Kumar A et al., 2008). 
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Both mTORC1 and mTORC2 play critical roles in maintaining the proper 
functionality of pancreatic β-cells, in this way being essential to regulate insulin 
secretion and hence guaranteeing all metabolic profile. For what concerns mTORC1, it 
has been assessed that when constitutively active it is able to increase β-cells size and 
number and to decrease concentration of blood glucose and insulin, resulting in an 
improved glucose tolerance, probably through an S6K1-mediated mechanism. 
Interestingly mTORC1 is involved as well in the so called β-cells compensation 
process, usually observed in conditions of high-fat diet or obesity. In such pathological 
states, nutrient excess and peripheral insulin resistance represent stimuli to pancreas to 
produce more insulin, which results in a raised formation of new β-cells from 
progenitors, together with proliferation and hypertrophy of pre-existing ones, with the 
final consequence being represented by an elevation of insulin synthesis and release. 
This adaptation on long time spans has anyway deleterious consequences, from two 
different point of view: first, β-cells cannot sustain such a proliferative and productive 
stress consequently resulting in the development of type 2 diabetes, and second a 
prolonged activation of mTORC1/S6K1 signaling leads to a feedback inhibition of 
IRS1 and IRS2, and hence to a decline of insulin responsiveness in islets, which has 
also been observed to be associated to decrease in cell vitality and increased apoptosis 
(Shigeyama Y et al., 2008). Recently mTORC2 has been found to have a role in this 
story, as shown in rictor null mice that exhibit reduction in β-cell mass, β-cell 
proliferation, pancreatic insulin content, and glucose-stimulated insulin secretion, 
which result in mild hyperglycaemia and glucose intolerance. These changes have 
been associated to a decrease in Akt phosphorylation at Ser473 and increased 
abundance of FoxO1 (Gu Y et al., 2011). 
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In the liver several key metabolic pathways are controlled by mTORC1 ad mTORC2, 
being of essential importance in the normal homeostasis of this organ, but as well 
involved in the onset of several hepatic pathological condition, such as for example 
nonalcoholic fatty liver disease (NAFLD). As described above for muscle and adipose 
tissue, in a normal physiological state mTORC1 activation stimulates lipogenesis 
through a SREBP1c-mediated mechanism in a still unknown way, and inhibits 
ketogenesis by inducing nuclear accumulation of nuclear receptor corepressor 1 
(NCoR1), which in turn blocks the activity of PPAR-α (Yecies JL et al., 2011; 
Sengupta S et al., 2010). On the other hand, in a condition of nutrient overload and 
obesity, mTORC1/S6K1 activity is increased, which results in an inhibition of IRS1 
activity with the consequent development of insulin resistance (Tremblay F et al., 
2007). Interestingly, the high rates of activation of mTORC1 due the elevated levels of 
proinflammatory cytokines and nutrients typically found in insulin resistant conditions 
could explain why lipogenesis remains very active aggravating further the pathological 
profile (Peterson TR et al., 2011).  For what concerns the role played by mTORC2, 
several evidences suggest that a blockage of PI3K/Akt signaling results in an increased 
gluconeogenesis, contributing to hyperglycaemia and to onset of hyperinsulinemia. In 
addition, a recent paper shed some light on these topics recognising the essential role 
of mTORC2 in driving lipogenesis independently to Akt2 activation, whereas 
gluconeogenesis seems to be mTORC2–independent (Yuan M et al., 2012).  
 
 
 
 
 
61 
 
3.5.1  Role of Fructose in NAFLD 
In the last years many researchers and clinicians focused their attention on the role 
played by fructose in metabolic diseases, such as obesity, type 2 diabetes, metabolic 
syndrome, as well as in liver specific pathologies, one of the most extensively studied 
being certainly Non Alcoholic Fatty Liver Disease (NAFLD). This huge debate about 
the role of fructose probably raised as a consequence of the recent increased diffusion 
of sweetened foods and beverages, such as cereal and chocolate bars or drinks such as 
regular sodas, energy and sport drinks. These aliments are typically produced using 
High Fructose Corn Syrup (HFCS), which is a sweetener obtained by corn starch to 
yield glucose, and then by processing glucose to have a syrup containing variable 
percentage of fructose, the most common used being the so called HFCS55, that means 
55% fructose-45% glucose, about the ratio found in sucrose (White JS, 2008). From a 
strictly biochemical point of view, fructose is theoretically capable of having some 
adverse effect, especially for what concerns triglyceride levels, considering its peculiar 
hepatic metabolism, which is prone to induce the formation of VLDL-triglyceride 
(Henry RR, Crapo PA, 1991). However, no evidences have been collected so far 
showing that fructose could have harmful effects in healthy subjects consuming an 
isocaloric, balanced diet, which also include fructose. Data obtained from 
epidemiological studies seem to assess a role of fructose-containing beverages in 
increasing body weight and obesity, but considering that these beverages are often 
associated with other sort of junk, high-fat foods, such as processed meats and fried 
potatoes, in a context of an elevated total energy intake, scarce consumption of fresh 
vegetables and fruits and physical activity, it is difficult to determine the real 
contribution fructose in these observations (Mozaffarian D et al., 2011). Indeed, 
another recent study demonstrated that fructose was able to induce an increase in body 
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weight only when associated with a hypercaloric diet, not when in the context of an 
isocaloric, balanced diet (Sievenpiper JL et al., 2012 [b]). This perspective is further 
confirmed by a paper that collects many evidences showing no effects of fructose on 
body weight and plasma triglycerides levels when consumed in amounts typically 
associated with a normal isocaloric Western diet, in both healthy, normal weight 
individuals as well as in overweight, obese people (Dolan LC et al., 2010 [a]; Dolan 
LC et al., 2010 [b]). Several clinical studies seem to confirm these epidemiological 
observations, revealing that fructose can be considered seriously harmful only when 
consumed at very high doses, and particularly in overweight or obese subjects. In 
particular, it has been reported that fructose overconsumption was able to alter lipid 
metabolism, inducing dyslipidemia and increase in blood glucose, without affecting 
insulin sensitivity, in the case of a moderate overfeeding (Lê KA et al., 2006). 
Employing higher fructose concentrations for a longer period coupled to a hypercaloric 
diet, slightly different but still coherent results were obtained, with a moderate 
augment of circulating triglycerides and ectopic fat deposition, together with a 
decrease in hepatic insulin sensitivity. These values were significantly higher in 
healthy offspring of patients with type 2 diabetes, a subgroup of individuals prone to 
develop metabolic disorders (Lê KA et al., 2009). Moreover, when compared to 
glucose overfeeding in a context of a hypercaloric diet in healthy males, fructose 
overfeeding resulted in comparable or lighter effects in all the metabolic parameters 
taken in account (Ngo Sock ET et al., 2010). Shifting attention to the liver, it seems 
likely that the augmented hepatic fat deposition observed during fructose overload 
trials might be explainable admitting a stimulation of de-novo lipogenesis, together 
with an inhibition of lipid oxidation (Lê KA et al., 2009). Interestingly, in rodent 
studies it has been shown that fructose was responsible for an increased hepatic 
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inflammation, in this way favouring the transition from a steatotic condition to 
steatohepatitis. In fact, in mice it has been demonstrated that a high-fructose diet was 
able to induce a TNFα-mediated steatosis and insulin resistance, together with an 
increased neutrophil infiltration, suggesting that fructose may be involved in the onset 
of steatohepatitis as a proinflammatory agent (Kanuri G et al., 2011). Similarly it has 
been shown that a high fat coupled to a high fructose diet determined an increased 
hepatic ROS production and a NASH-like phenotype with significant fibrosis 
(Abdelmalek MF et al., 2010). The mechanism of fibrosis may involve an increased 
hepatic oxidative stress associated with hepatic macrophage aggregation, which in turn 
induces a TGFβ1-signaled collagen deposition and histologically evident hepatic 
fibrosis (Kohli R et al., 2010). Hence it seems probable that fructose, when consumed 
in excess, might have a proinflammatory effect at the hepatocyte level that, if 
associated with the other typical risk factors such as calories surplus coupled with high 
prevalence of fats in the diet and scarce physical activity, may constitute an additional 
stimulus to progression to NASH. Interestingly, a recent study carried out in mice 
suggested that a chronic intake of high doses of fructose was able to induce a huge 
bacterial overgrowth at the intestine level, that together with an increased permeability, 
finally resulted in an endotoxin-dependent activation of hepatic Kupffer cells, which 
can contribute to the onset of hepatic insulin resistance through a TNFα-mediated 
mechanism (Spruss A et al., 2009).           
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Figure 24  Fructose & NAFLD: schematic representation of the possible role played by fructose in the 
induction of NAFLD (from Spruss A, Bergheim I, 2009). 
 
Finally it is useful to underline that until now there are no convincing evidences 
supporting the idea that fructose could in some way weaken the control of food intake, 
inducing a hyperphagic feeding behaviour (Soenen S et al., 2007; Moran TH, 2009). 
Anyhow, a recent research pointed out that carbohydrates in liquid form, such as those 
found in sugar- or HFCS-sweetened beverages, produced less satiety if compared with 
solid carbohydrates, leading to an increase in total long-term energy intake (Pan A, Hu 
FB, 2011). 
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AIM OF THE WORK 
 
Non-Alcoholic Fatty Liver Disease (NAFLD) is nowadays considered one of the most 
diffused pathologic conditions affecting the liver especially in western world, where 
recent reports suggest that about 15% to 20% of the population could be affected, with 
an increasing incidence of people at risk to develop this pathology (Anderson N, 
Borlak J, 2008). The frequency is much higher in obese population, for which 
epidemiological studies report percentages that ranges from 57.5% to 74%. NAFLD 
has been described in children as well, with 2.6% occurrence in non-obese, which rises 
to 22.5% in obese ones (Angulo P, 2002). 
The pathological mechanisms that induce the development of NAFLD are so far not 
completely clarified and still matter of debate, even if some key factors have been 
identified. Several theories have been proposed to date, but now most researchers 
believe that the first step required for NAFLD to develop is onset of insulin resistance, 
according to what hypothesised by Day CP and James OFW in 1998. Insulin 
resistance, in turn, would lead to an increase in fat accumulation, and hence to a 
pathological steatosis, probably inducing modifications in the uptake, synthesis, 
oxidation or export of lipids (Angulo P, 2002). 
Onset of insulin resistance is certainly one of the most intriguing and challenging 
topics to deal with in cellular and molecular biology, considering that many cellular 
processes involved have been identified until now, but that many others remain 
obscure so far. For what concerns the liver, the first step that is able to trigger insulin 
resistance is lipid accumulation due to a dietary fat overload. 
In the liver, insulin binding to its own receptor (IR) present in the plasma membrane 
leads to activation of its tyrosine kinase activity that result in phosphorylation of 
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Insulin Receptor Substrate proteins 1 and 2 (IRS1/2), event which in turn is able to 
activate Akt2 by means of several steps. Activated Akt2 determines the activation of 
glycogen synthase (GS), suppression of gluconeogenesis, and promotion of de novo 
lipogenesis through SREBP1c activation. Several distinct as well as overlapping 
biochemical deregulations can perturb this pathway. First of all, it has been shown that 
lipid accumulation is able to induce an increase in diacylglycerol (DAG) content, 
which is a well-known activator of protein kinase C (PKC) family.  In the liver raised 
levels of DAG lead to activation of PKCε, which is supposed to lead to impairment of 
IR activity, and of PKCδ that has been reported as well to play a role, probably by 
influencing lipid homeostasis. Interestingly PKCδ seems to be able to respond to the 
proinflammatory milieu that can arise as a consequence of a continuative 
hyperlipidemia, probably through IL6R or IKK-β. Ceramides as well are probably 
involved through the activation of PP2A, which in turn dephosphorylate Akt2, 
impairing its functionality. Moreover ceramides are able to block the dissociation of 
the complex PKCζ•Akt2 that normally occurs after insulin stimulation, again impeding 
Akt2 effects. 
So far several pathological conditions have been shown to be induced by the non 
proper functioning of the mTOR-activated pathways, including tumours, 
neurodegenerative processes, obesity and type 2 diabetes. For this reasons, many 
research groups worldwide are actually studying this topic, trying to find 
pharmacological approaches useful from a therapeutic point of view. 
From a biochemical point of view, mTOR can be classified as an atypical Ser/Thr 
protein kinase, included in the broad family of phosphoinositide 3-kinase (PI3K)- 
related kinase. Usually it interacts with different proteins, which confer to mTOR 
peculiar characteristics that define its physiological functions. Depending on which 
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proteins mTOR associates with, it forms two different complexes with different roles 
and sensitivity to rapamycin, termed mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2) (Laplante M, Sabatini DM, 2012). 
At the present time more data have been collected about mTORC1 with respect 
mTORC2, even though now many efforts are addressed on mTORC2.  
Several factors connected to the energetic status of the cell have been shown to be 
responsible for the activation of mTORC1, i.e. oxygen, amino acids, energy levels as 
well as growth factors, having as an outcome the control of some of the most 
important cellular processes, such as macromolecule biosynthesis, for instance lipid 
and proteins, cell cycle progression, autophagy, lysosome biogenesis, cell growth and 
metabolism.  
For what concerns mTORC2, it is known that it is activated by growth factors such as 
insulin, and that it regulates cell survival, metabolism and cytoskeletal organisation. 
Two main pathways downstream mTORC2 have been identified to date, both ones 
involving chains of phosphorylation events, but leading to different outcomes. The 
most characterised pathways are those involving Akt and serum- and glucocorticoid-
induced protein kinase 1 (SGK1). mTORC2 directly phosphorylates Akt on the critical 
Ser473 residue, resulting in its full activation (Sarbassov DD et al., 2005), which in 
turn affects several essential cellular processes, such as metabolism, growth and 
proliferation, survival and apoptosis, at the level of many tissues. It is possible to say 
that when mTORC2 is defective, the consequent lack of Akt functionality results in 
impaired phosphorylation of several key Akt targets, such as forkhead box O1/3A 
(FoxO1/3A).  
In the liver several key metabolic pathways are controlled by mTORC1 ad mTORC2, 
being of essential importance in the normal homeostasis of this organ, but as well 
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involved in the onset of several hepatic pathological conditions, such as for example 
nonalcoholic fatty liver disease (NAFLD). In a normal physiological state mTORC1 
activation stimulates lipogenesis through a SREBP1c-mediated mechanism in a still 
unknown way, and inhibits ketogenesis by inducing nuclear accumulation of nuclear 
receptor corepressor 1 (NCoR1), which in turn blocks the activity of PPAR-α (Yecies 
JL et al., 2011; Sengupta S et al., 2010). On the other hand, in a condition of nutrient 
overload and obesity, mTORC1/S6K1 activity is increased, which results in an 
inhibition of IRS1 activity with the consequent development of insulin resistance 
(Tremblay F et al., 2007). Interestingly, the high rates of activation of mTORC1 due to 
the elevated levels of proinflammatory cytokines and nutrients typically found in 
insulin resistant conditions could explain why lipogenesis remains very active 
aggravating further the pathological profile (Peterson TR et al., 2011).  For what 
concerns the role played by mTORC2, several evidences suggest that a blockage of 
PI3K/Akt signaling results in an increased gluconeogenesis, contributing to 
hyperglycaemia and to onset of hyperinsulinemia. In addition, a very recent paper shed 
some light on these topics recognising the essential role of mTORC2 in driving 
lipogenesis independently of Akt2 activation, whereas gluconeogenesis seems to be 
mTORC2–independent (Yuan M et al., 2012).  
In the last years many researchers and clinicians focused their attention on the role 
played by fructose in metabolic diseases, such as obesity, type 2 diabetes, metabolic 
syndrome, as well as in liver specific pathologies, the most extensively studied being 
certainly Non Alcoholic Fatty Liver Disease (NAFLD). This huge debate about the 
role of fructose probably rose as a consequence of the recent increased diffusion of 
sweetened foods and beverages, which are produced typically using High Fructose 
Corn Syrup (HFCS) (White JS, 2008). 
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Several clinical studies seem to agree with the observation that fructose can be 
considered seriously harmful when consumed at very high doses, and particularly in 
overweight or obese subjects. In particular, it has been reported that fructose 
overconsumption was able to alter lipid metabolism, inducing dyslipidemia and 
increase in blood glucose, without affecting insulin sensitivity, in the case of a 
moderate overfeeding (Lê KA et al., 2006). Employing higher fructose concentrations 
for a longer period coupled to an hypercaloric diet, slightly different but still coherent 
results were obtained, with a moderate augment of circulating triglycerides and ectopic 
fat deposition, together with a decrease in hepatic insulin sensitivity. These values 
were significantly higher in healthy offspring of patients with type 2 diabetes, a 
subgroup of individuals prone to develop metabolic disorders (Lê KA et al., 2009). 
Moreover, when compared to glucose overfeeding in the context of a hypercaloric diet 
in healthy males, fructose overfeeding results in comparable or lighter effects in all the 
metabolic parameters taken in account (Ngo Sock ET et al., 2010). Shifting attention 
to the liver, it seems likely that the augmented hepatic fat deposition observed during 
fructose overload trials might be explainable admitting a stimulation of de-novo 
lipogenesis, together with an inhibition of lipid oxidation (Lê KA et al., 2009). 
Nonetheless until now no evidences have been collected about the role played by 
fructose per se in an in vitro system, without any systemic or physiological influence, 
and no information is present on the possible pathways it might activate.  
Considering this background, aim of this work was to develop an in vitro model for 
NAFLD, with particular reference to the first “hit”, that is onset of steatosis and insulin 
resistance. Moreover, we tested the effects on steatosis and insulin resistance of 3,5-
diiodothyronine and 3,3’-diiodothyronine, trying to assess potential mechanisms of 
action, considering that, as described in the introduction, these molecules were shown 
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to influence lipid metabolism in other experimental systems and might, due to their 
similarity with T4 and T3, activate cellular signaling pathways. The experiments 
described in this work were performed in two different experimental systems, rat 
primary hepatocytes cultured on collagen-coated dishes, and human primary 
hepatocytes cultured on Matrigel-coated dishes. In the first, the effect of oleic acid and 
fructose on triglycerides accumulation and insulin resistance induction was taken in 
account, together with the effect of 3,5-diiodothyronine on the same parameters. To 
evaluate the induction of insulin resistance, three markers were used, i.e. the levels of 
expression of p85α subunit of PI3K, PTEN and Akt. Moreover we looked at Akt 
phosphorylation as well, to evaluate both insulin resistance and the effect of 3,5-
diiodothyronine. In the second experimental model used, attention was concentrated 
on the analysis of the effects of 3,5-diiodothyronine and 3,3’-diiodothyronine as lipid 
lowering agents, and on their ability to activate insulin signaling, trying to discover the 
molecular signaling pathways involved. In particular, the effect on Akt and FoxO1 
phosphorylation was analysed as markers of activation of the insulin pathway, and the 
possible involvement of mTORC2 as a mediator of the action of these two molecules 
was studied as well.       
  
 
 
 
 
 
 
 
71 
 
MATERIALS and METHODS 
 
1. MATERIALS 
 
1.1  Chemicals 
All chemicals were purchased from SIGMA, ALDRICH, SIGMA-ALDRICH and 
MERCK.   
 
1.2  Antibodies 
Rat primary hepatocytes 
Primary antibodies were purchased from Cell Signaling TECHNOLOGY
®
: PI3 Kinase p85 
(19H8) [cat. #4257], Akt (pan) (11E7) Rabbit mAb [cat. #4685], PTEN (D5G7) Rabbit 
mAb [cat. #5384] and from SIGMA-ALDRICH
®
: Rabbit Anti-Actin [cat. #A2066].  
Human primary hepatocytes 
Primary and secondary antibodies were purchased from Cell Signalling TECHNOLOGY
®
: 
Akt2 (D6G4) Rabbit mAb [cat. #3063]; Phospho-Akt (Ser473) (D9E) XP
®
 Rabbit 
mAb [cat. #4060]; FoxO1 (C29H4) Rabbit mAb [cat. #2880]; Phospho-FoxO1 
(Ser256) Antibody [cat. #9461]; Rictor (53A2) Rabbit mAb [cat. #2114]; mTOR 
(7C10) Rabbit mAb [cat. #2983], Anti-rabbit IgG, HRP-linked Antibody [cat. #7074].   
 
1.3  Solutions 
Rat primary hepatocytes 
Hank I and Hank II 
A stock solution was prepared in the following way: 140 mM NaCl, 5 mM KCl, 0.8 
mM MgSO47H2O, 0.34 mM Na2HPO4, 0.44 mM KH2PO4, 6 mM NaHCO3, 3 mM 
Hepes. Using this stock solution, Hank I and Hank II were then made in this manner: 
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Hank I adding 2% Bovine Serum Albumin (BSA), 0.06 mM EGTA and Hank II with 
0.5 mM CaCl22H2O and collagenase; pH of both solutions should be set to 7.4. 
Krebs-Henseleit 
A stock solution was prepared in the following way: 240 mM NaCl, 9.6 mM KCl, 2.4 
mM MgSO47H2O, 0.34 mM Na2HPO4, 2.4 mM KH2PO4, 3.9 mM CaCl22H2O, 50 
mM NaHCO3, 3 mM Hepes. This stock solution has to be completed with 2% Bovine 
Serum Albumin (BSA) and 12.5 mM Hepes to obtain the working solution. 
Phosphate Buffered Saline (PBS) 
PBS was prepared with 170 mM NaCl, 3.35 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4, 0.68 mM CaCl22H2O, 0.49 mM MgCl26H2O. 
Tris Buffered Saline 
50 mM Tris, 150 mM NaCl, pH 7.4 with HCl 
Human primary hepatocytes 
Perfusion buffer 1 (P1 medium) 
P1 medium was prepared adding 0.5 mM EGTA (234.2 mg/L), 0.5% w/v BSA, and 50 
µg/mL ascorbic acid in Ca
2+
- and Mg
2+
- free Hank’s Balanced Salt Solution (HBSS) 
without phenol red. 
Perfusion buffer 2 (P2 digestion medium) 
P2 digestion medium was prepared dissolving 0.025% w/v collagenase XI (250 mg/L 
and 0.5% w/v BSA in Eagle’s Minimum Essential Medium with Earle’s salts 
(EMEM). This buffer is typically used 100 mL/10 g liver. 
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2. METHODS  
2.1  Adult Rat Primary Hepatocytes 
Hepatocytes were obtained with a perfusive enzymatic method, according to the 
procedure originally described by Moldeus and colleagues (Moldeus P et al., 1978), 
and successively revised by De Colli and colleagues (De Colli M et al., 1981). 
Briefly, rats were anesthetized by intraperitoneal administration of sodium 
pentobarbital (5 mg/100 g body weight). The liver was perfused firstly with a calcium-
free Hank’s balanced salt solution containing 2% BSA and 0.6 mM EGTA acid, and 
secondly with Hank’s solution containing 4 mM calcium chloride and 0.04% 
collagenase. Hepatocytes were released into a Krebs-Henseleit buffer with 2% BSA 
and subsequently seeded in 35 or 60 mm collagen-coated dishes. 
 
2.2  Foetal Rat Primary Hepatocytes 
Hepatocytes were obtained using a non-perfusive enzymatic method, according to the 
procedure described by Conti DeVirgiliis and colleagues (Conti DeVirgiliis L et al., 
1981). 
Briefly, livers extracted from rats at 21
th
 day of intrauterine life, were cut in very small 
pieces until achieving a homogeneous appearance. This homogenate was then washed, 
once at room temperature under hood and trice for 10’ at 37°C in a tempering bath 
under 95% O2 and 5% CO2 with Hank I solution, to remove calcium and blood. 
Washed homogenate was subsequently subjected to four enzymatic digestions, 10’ 
each, with Hank II solution containing collagenase and CaCl22H2O, in the same 
tempering bath at 37°C under 95% O2 and 5% CO2. At the end of every digestion, the 
supernatant was collected, diluted with Krebs-Henseleit solution and then centrifuged 
two times for 5’ at 4°C. Cells collected after centrifugations were diluted in 5 mL 
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Krebs-Henseleit, counted in a Thoma-Burke chamber after Trypan Blue staining and 
finally plated in 35 mm collagen-coated dishes.   
 
2.3  Human Primary Hepatocytes 
Human Primary Hepatocytes were isolated by means of a perfusive enzymatic method, 
as originally described by Ballet F and colleagues (Ballet F et al., 1984), and 
subsequently revised by LeCluyse EL and Alexandre E (LeCluyse EL, Alexandre E 
2010). 
Adult human livers are usually obtained from patients undergoing surgical liver 
resection due to metastatic tumours, from brain-dead-but-beating-heart donors, or from 
dead people.  
All the perfusion apparatus, including tempering water baths, heating devices and 
peristaltic pumps, and hence the entire procedure should be performed inside a 
biosafety cabinet. One to three vessels were cannulated and connected to a peristaltic 
pump, and the liver was placed into a tank containing warm HBSS until it was 
completely submerged. The tissue was perfused with P1 medium, then with P1 
medium without EGTA and finally with P2 digestion medium for 20-25 minutes. After 
complete digestion was achieved, as revealed by softening and structural breakdown of 
the parenchyma, and enlargement of the tissue, the liver was disaggregated by 
chopping with scissors, releasing the hepatocytes which were in turn filtered, using 
two layers of gauze, centrifuged at 50 g for 5 minutes and washed twice with EMEM. 
The cells were counted with a Thoma-Burke chamber after Trypan Blue staining and 
then plated in 6-well plate culture dishes precoated with Matrigel [BD Matrigel
™
 
Basement Membrane Matrix, 10 mL vial, Cat. 354234], 1.5•106 per well. 
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Hepatocytes were cultured in Swedish Media from William’s E medium (WE-SWE), 
obtained supplementing William’s E medium with 2 mM Glutamine, 20 mM Hepes, 
10 nM Insulin, 0.01 M Gentamicin, 0.055 µM (0.05 µg/mL) and 100 nM 
Dexamethasone. All concentrations reported should be read as final concentrations in 
the culture medium.     
      
2.4  Protein determination 
Protein concentration was assessed according to the method originally described by 
Lowry OH et al. (1951) and later reviewed by Peterson GL (1979). This assay is based 
on a two step reaction that finally leads to development of a blue colour, first step 
being represented by the interaction between protein and copper in an alkaline 
medium, followed by reduction of Folin phenol reagent, which was described for the 
first time by Folin O, Ciocalteu V in 1927. The reactive component of this mixture is 
the phosphomolybdic-tungstic mixed acid that is the final chromogenic in the assay 
and includes the following chemical species: 3 H2O, P2O5, 13/14 WO3, 5/4 MoO3, 10 
H2O. Colour production is essentially provoked by amino acids tyrosine and 
tryptophan, even if also cystine, cysteine and histidine give some contributes. These 
amino acids react with the Folin reagent, inducing the loss of 1,2, or 3 oxygen atoms, 
generating one or more possible reduced species, which give raise to the typical blue 
colour with maximum absorbance at λ=750 nm and minimum absorbance at λ=405 
nm. Copper by chelating the peptide structure seems to facilitate the electron transfer 
to the chromogenic species, especially near to amino acids functional groups, in this 
way improving the sensitivity of the test.  
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Adult and Foetal Rat Primary Hepatocytes 
A standard curve was constructed using Bovine Serum Albumin (BSA) 0.1 mg/mL.  
Briefly, an aliquot of each sample, variable from 5 to 20 μL depending on the 
experiment, was diluted to 200 μL DH2O. Subsequently 1 mL solution “A” + “B” 
(100/1 v/v) was added, and after 10 minutes incubation, 100 μL solution “C” was 
inserted. After 30 minutes of incubation, absorbance was measured at λ=660 nm 
employing a Thermo Spectronic “GENESYS 10-S UV scanning” [Cat. 335907-02] 
spectrophotometer. 
Solution “A”: NaK tartrate 200 mg/L, Na2CO3 20 g/L, NaOH 4 g/L dissolved in 
DH2O; Solution “B”: CuSO4 0.1 g/L dissolved in DH2O; Solution “C”: Folin-
Ciocalteu, diluted in a 1:1 ratio with DH2O. 
Human Primary Hepatocytes 
Protein determination was performed employing the Bio-Rad DC Protein Assay 
Reagents Package [Cat. 500-0116], which includes: REAGENT A, an alkaline copper 
tartrate solution and REAGENT B, a dilute Folin Reagent. Protein concentration 
measurement was realised on 96 well microplates, using a Bio-Rad Protein Standard I  
(Lyophilized Bovine Plasma Gamma Globulin) [Cat. 500-0005] to build a standard 
curve, and absorbance was evaluated using a “Tecan Infinite 500” plate reader and 
“Magellan7” software.  
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2.5  Oil Red O staining (ORO) 
Oil Red O (ORO) (1-(2,5-dimethyl-4-(2-5-dimethylphenyl) phenyldiazenyl) 
azonapthalen-2-ol, or Solvent Red 27, Sudan Red 5B, C.I. 26125, C26H24N4O) is a 
lysochrome (fat-soluble dye) diazo dye used for staining of neutral triglycerides and 
lipids. The basis for these dyes colouring fats resides in their capacity to dissolve into 
them, in other words the fat acting as a solvent for the dye. In fact lysochromes are 
mostly insoluble in strongly polar solvents, such as water, somewhat more in less polar 
solvents, such as ethanol, but are quite strongly soluble in non-polar solvents, such as 
xylene. Triglycerides, being non-polar compounds, dissolve them quite well, as do 
other lipids that show fatty components.  
ORO has the appearance of a red powder with maximum absorption at 518 (359) nm. 
It belongs to the same family of dyes that includes Sudan II, Sudan III, Sudan IV, and 
Sudan Black B, which are characterized to the high affinity to fats, and then widely 
used to show neutral lipids, triglycerides and lipoproteins. Anyway, due to its deeper 
red colour resulting in a better quality of the staining, ORO has generally replaced 
Sudan dyes.    
Typically, after the cell culture medium was removed, dishes were washed with PBS 
and incubated for 10 minutes with 10% formalin in 10X PBS. Formalin was then 
discarded and after another 1 h incubation with fresh 10% formalin, cells were washed 
twice with DH2O and one time with 60% 2-propanol for 5 minutes. Cells were let to 
dry under hood, subsequently incubated 10 minutes with ORO, and then washed four 
times with DH2O. Photos were acquired, ORO was eluted with 100% 2-propanol and 
absorbance was measured at λ=500 nm, using 100% 2-propanol as a blank. 
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Oil Red O [SIGMA Cat. O0625] was preliminary dissolved as follows: 0.35% w/v in 
100% 2-propanol. Then this stock solution was diluted 60% v/v in DH2O to obtain the 
working solution used during experiments.    
 
 
 
2.6  Neutral Red staining Cytotoxicity Assay 
Neutral Red (3-amino-7-dimethylamino-2-methylphenazine hydrochloride) or 
toluylene red, Basic Red 5, C.I. 50040, C15H17ClN4) is a slightly cationic dye that 
easily passes through cell membranes and localises especially inside lysosomes. The 
acidic milieu typical of these organelles favours the development of a red staining 
(pH<6.8 give rise to red, pH>6,8 produces orange-yellow). 
Toxic treatments are able to induce alterations and damages to cell membranes, 
including lysosomal ones, resulting in the lost of any acidic compartment inside the 
cells: in these condition neutral red develops an orange-yellow staining. 
This background draws the rationale for the use of this molecule as a cell vitality test, 
also considering that it is no harmful for health, quite cheap, and easy to perform. 
Usually 1 mg/mL solution in DH2O of Neutral Red [SIGMA Cat. N7005] is prepared 
and added to culture medium to achieve a final concentration of 10 μg/mL in the dish. 
After 1h incubation at 37°C, culture medium was discarded, and cells were washed 
twice with PBS. Neutral Red was eluted using acetil-ethanol, prepared by mixing 
glacial acetic acid with 50% v/v ethanol/DH2O in 1:99 ratio. 
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Absorbance was measured at λ=540 nm, using acetil-ethanol as a blank, and values 
were normalised for protein content. 
 
 
 
2.7  Lipid extraction and triglycerides measurement 
After the cell culture medium was discarded, dishes were washed twice with PBS and 
let dry at room temperature under hood. Lipids were extracted employing a mixture 
Hexan:Isopropanol (3:2), in two consecutive times 1 h and 30 minutes each 
respectively, and plates were let dry under hood until residual solvent was completely 
evaporated. Protein concentration was evaluated with the Lowry procedure, after 
dissolving cells in 1 M NaOH overnight.  
The lipid extract was dried under N2 flow at 40°C using a needle analytical evaporator 
[The MEYER N-EVAP. ANALYTICAL EVAPORATOR Organomation 
ASSOCIATE INC. P.O., Box 159 South Berlin MA 01549], then dissolved in CHCl3 
and dried again under N2 flow at 40°C. The extract was suspended in CHCl3+1% 
Triton X-100 and dried again. DH2O was finally added until the solution is completely 
clear. Triglycerides content was evaluated with an enzymatic colorimetric test [TG 
Triglycerides GPO-PAP – Roche/Hitachi Cat. 12016648] based on the following 
reactions: 
Triglycerides + 3H2O    
LPL         
glycerol + 3RCOOH 
Glycerol + ATP     
GK              
glycerol-3-phosphate + ADP 
Glycerol-3-phosphate + O2      
GPO
          dihydroxyacetone phosphate + H2O2 
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H2O2 + 4-aminophenazone + 4-chlorophenol    
PEROXIDASE         
4-(p-benzoquinone-
monoimino)-phenazone + 2 H2O +HCl 
This method is derived from that described by Wahlefeld AW et al., 1974, and utilises 
a microorganisms-derived lipoprotein lipase to completely hydrolyse triglycerides to 
glycerol, which in turn is oxidised to dihydroxyacetone phosphate and hydrogen 
peroxide. The hydrogen peroxide is subsequently involved in a peroxidase-catalysed 
reaction with 4-aminophenazone and 4-chlorophenol, the product of which is a 
red/orange dye (Trinder endpoint reaction). The colour intensity is directly 
proportional to the triglycerides concentration and can be evaluated reading 
absorbance at λ=492 nm using a “Tecan Infinite 500” plate reader and “Magellan7” 
software, utilising a standard curve constructed using the “Precinorm 120214” 
standard. 
 
2.8  Transfection with siRNAs 
Human primary hepatocytes cultured on Matrigel were transfected with two siRNAs 
specific for subunit Rictor of mTORC2 [Cell Signaling TECHNOLOGY
®
: SignalSilence
®
 
Rictor siRNA I, cat. #8649 and SignalSilence
®
 Rictor siRNA II, cat. #8622], and with 
a scrambled siRNA to verify the efficiency of transfection [Cell Signaling 
TECHNOLOGY
®
: SignalSilence
®
 Control siRNA, cat. #6568]. Transfection was performed 
using Lipofectamine
®
 RNAiMAX Reagent [Invitrogen
™
 cat. 13778-030], diluted with 
Opti-Mem I [Invitrogen
™
 cat. 11058-021]. To achieve a good efficiency of 
transfection cell density at plating was set to 0.75106/mL, 8 μL Lipofectamine®/well 
and 10 μL siRNAs/well were used.       
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2.9  Immunoelectrophoretic analysis  
Rat primary hepatocytes  
After the cell culture medium was removed, dishes were washed twice with ice-cold 
PBS, and cells were scraped, collected in PBS and centrifuged at 2200 rpm for 8 
minutes. Pellet was then solubilised in a lysis buffer containing 10% SDS, 0.125 M 
Tris/HCl pH 6.8, 1% PMSF, 1% Leupeptin, 1% Sodium Orthovanadate (NaVO4).  
Samples were prepared for western blotting using a loading buffer containing 40% 
SDS (8%) [Sodium dodecyl sulphate SIGMA Cat. L4509], glycerol (40%) [Glycerol 
SIGMA Cat. G6279], β-mercaptoethanol (20%) [2-Mercaptoethanol SIGMA Cat. 
M3148], bromophenol blue (0.04%) [Electrophoresis Purity Reagent Bromophenol 
Blue, Bio-Rad Cat. N. 161-0404], 0.0315 M Tris/HCl pH 6.8. 
Polyacrylamide gels were prepared using the following solutions: 
Resolving gel: 3 M Tris/HCl pH 8.8; Stacking gel: 0.5 M Tris/HCl pH 6.8; 
Acrylamide: 30% Acrylamide/Bis Solution, 29:1 (3,3% C) Acrylamide:N,N’-
Methylenbisacrylamid Electrophoresis Purity Reagent [Bio-Rad Cat. 161-0156]; 
TEMED: N,N,N’,N’-Tetramethylethylene-diamine, for electrophoresis, approx. 99% 
[SIGMA Cat. T9281]; APS: Ammonium Persulfate [Bio-Rad Cat. 161-0700]; protein 
denaturing agent: 10% SDS. 
Proteins were separated in a Bio-Rad Mini-PROTEAN
®
 3 Cell using the following 
running buffer: 10X Tris/Glycine/SDS Buffer for SDS-PAGE applications [Bio-Rad 
Cat. 161-0772]. Gels were blotted onto nitrocellulose membranes using the iBlot
™
 Dry 
Blotting System [Invitrogen
™
 Cat. IB1001], and subsequently stained with a 1% 
Ponceau Red solution in acetic acid [Ponceau S, practical grade – SIGMA Cat. P3504] 
to verify the blotting efficiency. After 1 h incubation at room temperature in blocking 
solution (5% defatted dry milk in TBS), membranes were incubated overnight at 4°C 
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with the primary antibody of interest. Secondary antibody incubation was performed 
for 1h at room temperature and bands revelation achieved using an ECL system 
[Thermo SCIENTIFIC SuperSignal
®
 West Dura Extended Duration Substrate, Cat. 
34075]. Densitometries were realised utilising ImageJ software, free downloadable on 
http://rsb.info.nih.gov/ij/.     
Human primary hepatocytes 
After the cell culture medium was removed, 6-well plates were washed twice with ice-
cold PBS, and cells were scraped, collected in PBS and centrifuged at 2200 rpm for 8 
minutes. Pellet was then solubilised in a lysis buffer containing 10% SDS, 0.125M 
Tris/HCl pH 6.8, 1 tablet of Complete, Mini, EDTA-free Protease Inhibitor Cocktail 
Tablets [Roche Cat. 11 836 170 001], 1 tablet of PhosSTOP – Phosphatase Inhibitor 
Cocktail Tablets [Roche Cat. 04 906 845 001]. 
Samples were prepared for western blotting using Laemmli Sample Buffer [Bio-Rad 
Cat. 161-0737] following producer’s directions for use. 
Proteins were separated with Novex
®
 10% Tris-Glycine Gel 1.0 mm x 10 wells 
[Invitrogen
™
 Cat. EC6075BOX], in an Invitrogen
™
 XCell SureLock
™
 Mini-Cell [Cat. 
EI0001], using the following running buffer: 10X Novex
®
 Tris-Glycine SDS Running 
Buffer [Invitrogen
™
 Cat. LC2675]. Gels were blotted onto Nitrocellulose Membrane 
[Invitrogen
™
 Cat. LC2001], using an Invitrogen
™
 XCell II
™
 Blot Module [Cat. 
EI9051], filled with a transfer buffer prepared as follows: 4% 25X Novex
®
 Tris-
Glycine Transfer Buffer [Invitrogen
™
 Cat. LC3675], 20% Methanol, 76% DH2O. After 
Ponceau Red staining, performed using SIGMA-ALDRICH Ponceau S solution (0.1 % 
w/v in 5% acetic acid) [Cat. P7170], membranes were destained with 0.5 M NaOH and 
subsequently incubated for 30 minutes at room temperature with a blocking solution 
[Thermo SCIENTIFIC Starting Block
™
 T20 (PBS) Blocking Buffer, Cat. 37539]. 
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Primary antibody incubation was carried out overnight at 4°C, whilst secondary 
antibody incubation was performed for 1h at room temperature; bands were revealed 
using an ECL system [Thermo SCIENTIFIC SuperSignal
®
 West Dura Extended 
Duration Substrate, Cat. 34075], and chemiluminescence was measured with the Bio-
Rad CHEMIDOC
™
 XRS System Universal Hood II and analysed employing the Bio-
Rad Quantity One
®
 Software.  
 
2.10 Statistical analysis 
Statistical calculations and graphing were performed using Graph Pad 4.01 software. 
The data were analysed for normality with the Kolmogorov-Smirnov test, and 
significance was assessed with a one-way ANOVA followed by Tukey’s HSD test for 
multiple comparisons. The data were considered significant when p value <0.05. 
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RESULTS 
 
The experiments described in this thesis have been performed employing two different 
experimental systems, rat primary hepatocytes (RPH) at adult and foetal stage cultured 
on collagen-coated dishes, and human primary hepatocytes (HPH) cultured on 
Matrigel-coated dishes. Although presenting several points of contact, such results will 
be hence described separately through this section. 
RPH   
As previously described, the aim of the study in RPH was to establish an in vitro 
model for the first “hit” of NAFLD and to evaluate in this system the role of fructose 
and the potential therapeutic role of 3,5-T2. 
As a steatogenic stimulus we used oleic acid, considering that in several other systems 
it was employed for such purpose (Vidyashankar S et al., 2013). Figure 1 shows the 
dose-response effect of oleic acid at concentrations ranging from 100 µM to 500 µM 
on triglycerides accumulation and cell viability, after 24 h of treatment. Histograms 
clearly demonstrate the effect of oleic acid in inducing triglycerides accumulation, 
with the maximum result obtained at 500 µM, with nearly double triglycerides content 
with respect to control. On the other hand, no significant detrimental effects were 
found on cell viability, regardless of the concentration used, permitting us to choose 
the concentration of 500 µM as an excellent compromise between cell viability and 
induction of triglycerides accumulation. 
For what concerns the effect of fructose, Figure 2 reports results of a dose-response 
analysis, obtained treating hepatocytes with concentrations ranging from 5 mM to 200 
mM. The range 5 mM to 20 mM is supposed to be physiological, whereas 
concentrations above these values should be considered strongly supraphysiological 
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(Segal MS et al., 2007). Our results clearly show that fructose exhibits a huge effect on 
triglyceride accumulation, comparable to that of oleic acid at the concentration of 50 
mM, but no significant effects were observed in the range 5 mM to 20 mM. 
Interestingly, at higher concentrations, i.e. 100 nM and 200 nM, the amount of stored 
triglycerides was lower with respect to what observed at 50 mM, and this probably 
makes sense, if these data are compared with the effect of fructose on cell viability, as 
shown in the panel B of the figure. In fact is clearly evident as fructose was able to 
induce a reduction in cell viability, starting with a modest effect at 20 mM, until a 
minus 70% at 200 mM. For all of these reasons we decided to exclude the two highest 
concentrations from the following experiments. 
In order to assess the effect of oleic acid and fructose when administered together, 
trying to simulate the typical condition of a western cafeteria diet, we treated 
hepatocytes for 24 h with 500 µM oleic acid and 5 mM to 50 mM fructose. Figure 3 
clarifies that, also when administered in conjunction with oleic acid, fructose was not 
able to induce a large increase in triglycerides accumulation if compared with oleic 
acid alone. Noteworthy, fructose kept its ability to induce cell death, even if the 
presence of oleic acid worsen such effect, as evidenced in the panel B of the figure.  
Considering that until now our model was able to reproduce steatosis without affecting 
cell viability, we turned our attention on insulin resistance, trying to evaluate if a 24 h 
treatment with oleic acid and fructose could be able to induce such a condition. For 
this purpose we considered two markers, i.e. p85α subunit of PI3K and PTEN, which 
in two different systems, one in vivo and one in vitro, have been shown to increase 
when in presence of insulin resistance conditions (Mauvais-Jarvis F et al., 2002; Shen 
YH et al., 2006; Lee SK et al., 2011). 
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For what concerns p85α, Figure 4A shows how 24 h treatment with 500 µM oleic was 
able to induce an increased expression of this subunit, whereas panel B suggests that 
fructose did not change p85α levels. In this perspective, Figure 5 demonstrates the 
positive effect of 24 h treatment with 500 µM oleic acid on PTEN expression, and 
these results together with those described previously strongly made us confident that 
the system we built could be considered with good approximation a steatotic and 
insulin resistant system. 
On this system we analysed the effect of 3,5-T2 on oleic acid-induced triglycerides 
accumulation, as reported in Figure 6. To investigate this aspect we utilised two 
different approaches, the first one consisting in treating hepatocytes with oleic acid and 
3,5-T2 contextually for 24 h, the second one in testing the effect of 24 h treatment with 
3,5-T2 after 24 h incubation with oleic acid. The results obtained using these two 
different approaches are reported in panel A and panel B respectively, and clearly 
demonstrate that 3,5-T2 in the range of physiological concentrations, i.e. 1 nM and 0.1 
nM, strongly reduced the triglycerides content, both if administered contextually with 
oleic acid or in a condition when triglycerides accumulation is well-established. These 
observations permit us to say that 3,5-T2 is able to prevent triglycerides storage inside 
the hepatocyte, and that it can revert the accumulation induced by oleic acid as well.  
Once assessed the role of 3,5-T2 as a lipid-lowering agent, the next step was to analyse 
the possible role played in the insulin signaling pathway, and for this reason the effect 
on phosphorylation of Akt at Ser473 residue was examined, considering that this 
phosphorylation is one of the key steps downstream the insulin receptor. The results 
obtained, which are reported in Figure 7, are indeed very interesting for at least two 
reasons. First of all, as reported in panel B, 3,5-T2 induced Akt phosphorylation 
comparably to insulin, and when this insulin-induced phosphorylation was inhibited 
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after 24 h incubation with oleic acid, 3,5-T2 was still capable to drive this 
phosphorylation, suggesting that most probably 3,5-T2 follows a different pathway 
with respect to insulin. Secondly, as reported in panel A, we found that after 24 h oleic 
acid load, the level of total Akt was increased of about 50% if compared to control, 
similarly to what shown for p85α and PTEN. Actually we are not able to explain this 
result, or to say if and in which way it could be interpreted as a sign of insulin 
resistance, but we can consider it as an interesting future topic of investigation.  
To conclude the description of results obtained in RPH, now several data obtained 
using foetal RPH will be reported, which are not conclusive and still opened to further 
investigations, but anyway interesting, considering that they show several differences 
with respect to what found in adult cells. For example, as reported in Figure 8 A and 
B, oleic acid seemed to be less steatogenic in foetal cells, but also more toxic, and 3,5-
T2 appeared completely ineffective in preventing triglycerides accumulation, even if 
not toxic. On the other hand, similarly to what already demonstrated in adult 
hepatocytes, 24 h incubation with 500 µM oleic acid was able to stimulate synthesis of 
p85α subunit of PI3K, as represented in Figure 9 A, whereas 24 h incubation with 10 
mM fructose did not affect such synthesis, as reported in Figure 9 B.   
HPH 
The experiments that will be described now with HPH were performed employing 
HPH cultured on Matrigel-coated dishes. Matrigel is a complex mixture of 
extracellular matrix proteins, originally isolated from the Engelbreth-Holm-Swarm 
mouse (EHS) sarcoma (Kleinman HK et al., 1982). This substrate allows to keep better 
in culture all the liver-specific characteristics of hepatocytes, such as morphology and 
several metabolic pathways (Ben-Ze’ev A et al., 1988), as described elsewhere in this 
thesis, giving the opportunity to work with a system resembling in most aspects a real 
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liver. Such morphological differences with respect to the usual collagen-grown 
hepatocytes is clearly noticeable in Figure 10, which reports two photos that were 
taken at two different magnification, 20X (A) and 40X (B).   
Utilising this system we tried to analyse the effect of both diiodothyronines, 3,3’-T2 
and 3,5’-T2 as lipid lowering agents, evaluating the total triglyceride content after 24 h, 
48 h and 72 h of treatment, using decreasing concentrations of the two 
diiodothyronines, starting with 100 nM until 0.1 nM. These experiments were carried 
out using hepatocytes obtained from two different patients, one female and one male. 
Figure 11 reports the results acquired with the female patient, which show a reduction 
in the triglycerides content after the treatment with both diiodothyronines. An 
analogous result was found in the male patient, after 24 h and 72 h, as evidenced in 
Figure 12. 
Once clarified that both diiodothyronines were able to reduce triglyceride content, 
attention was focused on their potential role in the stimulation of insulin signaling 
pathway, similarly to what already found in RPH. For such purpose we considered two 
well-known markers of this pathway, which are Akt and FoxO1. Again we utilised 
cells obtained from one male and one female patient, and for brevity one single 
experiment for each patient will be reported, considering that we obtained comparable 
results in both patients. Figure 13 reports the effect of 10 min. stimulation with 3,5’-T2 
and 3,3’-T2 on phosphorylation of Akt at Ser473 residue in a female patient (VF8, 
from the place of isolation), and the graphs clearly demonstrated the huge increase in 
phosphorylation obtained, in the order of 200% with respect to control. Figure 14 
reports the results obtained with the male patient (HF162, from the place of isolation),   
obtained blotting samples for phosphorylation of FoxO1 at Ser256, which is known to 
drive the proteasomal degradation of FoxO1, permitting the transcription of insulin-
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responsive genes (Zhang X et al., 2002; Matsuzaki H et al., 2003). Similarly to what 
reported for Akt, an increase in the phosphorylation in the order of 150-200% with 
respect to control was found, strongly suggesting a direct positive role of 
diiodothyronines in the activation of insulin signaling. 
Considering the data reported for RPH, which demonstrated that 3,5-T2 was able to 
induce the phosphorylation of Akt in an insulin-resistant system, the question on which 
pathway diiodothyronines might use to stimulate such activation was taken in account. 
Among all the possible pathways that could be used, my idea was that a probable 
mediator might be mTORC2, for all the reasons already specified in the introduction 
and in the aim of the work. To test this hypothesis, Rictor subunit of mTORC2 
complex was silenced using a siRNA approach, then hepatocytes were stimulated with 
3,3’-T2 for 10 min. and samples were blotted for Akt phosphorylated at Ser473 
residue. As reported in Figures 15 and 16, the phosphorylation of Akt at Ser473 
residue was completely blocked after treatment with siRNA(I) and siRNA(I+II), 
whereas only slightly reduced after silencing with siRNA(II) alone. Finally, to verify 
the efficiency of transfection, three different approaches were used, as shown in the 
last three figures. First of all cells were silenced with a scramble siRNA (control 
siRNA), to confirm that after such a silencing phosphorylation of Akt were still 
present, and indeed it was the case, as clearly demonstrated in Figure 17. Hence, to 
substantiate further this observation, the levels of Rictor and mTOR before and after 
silencing were evaluated, and results obtained confirmed that silencing was 
successfully achieved, and also that siRNA(I) resulted much more efficient if 
compared with siRNA(II).           
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Figure 1  
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Fig.1  Effect of Oleic Acid (OA) on triglycerides accumulation and cell viability in rat primary 
hepatocytes, assessed using Oil Red O staining (A) and Neutral Red staining (B). Cells were 
treated for 24 h with OA and then analysed according to the respective protocols, as described in 
Materials and Methods section. Data represent at least four different experiments performed in 
duplicate.  
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Figure 2  
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Fig.2  Effect of Fructose (Fruct.) on triglycerides accumulation and cell viability in rat primary 
hepatocytes, assessed using Oil Red O staining (A) and Neutral Red staining (B). Cells were 
treated for 24 h with Fruct. and then analysed according to the respective protocols, as described 
in Materials and Methods section. Data represent at least four different experiments performed in 
duplicate.  
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Figure 3  
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Fig.3  Effect of Oleic Acid (OA) plus Fructose (Fruct.) on triglycerides accumulation and cell 
viability in rat primary hepatocytes, assessed using Oil Red O staining (A) and Neutral Red 
staining (B). Cells were treated for 24 h with OA plus Fruct. and then analysed according to the 
respective protocols, as described in Materials and Methods section. Data represent at least four 
different experiments performed in duplicate.  
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Figure 4 
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Fig.4  Effect of Oleic Acid (OA) (A) and Fructose (Fruct.) (B) on p85 levels in rat primary 
hepatocytes, assessed by Western Blot. Cells were treated for 24 h with OA or Fruct. Western 
Blot was performed according to the procedure described in Materials and Methods section. Data 
represent at least three different experiments performed in duplicate.  
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Figure 5 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                               
 
                               
 
 
 
 
 
 
 
 
Fig.5  Effect of Oleic Acid (OA) on PTEN levels in rat primary hepatocytes, assessed by Western 
Blot. Cells were treated for 24 h with OA. Western Blot was performed according to the 
procedure described in Materials and Methods section. Data represent at least three different 
experiments performed in duplicate.  
 
C
tr
l M

O
A
 5
00
In
s 
10
0n
M
In
s 
1n
M
M
+I
ns
 1
00
nM

O
A
 5
00
M
+I
ns
 1
nM

O
A
 5
00
0
15
30
45
60
75
90
105
120
135
150
165 *
* p<0.01 compared to Ctrl
* *
%
 o
f 
C
tr
l
95 
 
Figure 6 
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Fig.6  Effect of 3,5-Diiodothyronine (3,5-T2) on Oleic Acid (OA)-induced triglycerides 
accumulation in rat primary hepatocytes, assessed using Oil Red O staining. Cells were treated 
for 24 h with OA plus 3,5-T2 (A), or treated for 24 h with OA and subsequently with 3,5-T2 for 
additional 24 h (B) and then analysed according to the respective protocol, as described in 
Materials and Methods section. Data represent at least four different experiments performed in 
duplicate.   
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Figure 7 
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Fig.7  Effect of Oleic Acid (OA) and 3,5-T2 on Akt phosphorylation at Ser473 residue in rat 
primary hepatocytes, assessed by Western Blot. Cells were treated for 24 h with OA and then 
stimulated for 15’ with Insulin (Ins) 100 nM and for 10’ with 3,5-T2 1 nM. Western Blot was 
performed according to the procedure described in Materials and Methods section. (A) Akt total; 
(B) Akt-P(Ser473). Data represent at least three different experiments performed in duplicate. 
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Figure 8  
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Fig.8  Effect of 3,5-Diiodothyronine (3,5-T2) on Oleic Acid (OA)-induced triglycerides 
accumulation and cell viability in foetal rat primary hepatocytes, assessed using Oil Red O 
staining (A),  and Neutral Red Staining (B). Cells were treated for 24 h with OA plus 3,5-T2 and 
then analysed according to the respective protocols, as described in Materials and Methods 
section. Data represent at least four different experiments performed in duplicate.  
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Figure 9  
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Fig.9  Effect of Oleic Acid (OA) (A) and Fructose (Fruct.) (B) on p85 levels in foetal rat primary 
hepatocytes, assessed by Western Blot. Cells were treated for 24 h with OA or Fruct. Western 
Blot was performed according to the procedure described in Materials and Methods section. Data 
represent at least three different experiments performed in duplicate.  
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Figure 10 
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Fig.10  Examples of Human Primary Hepatocytes (HPH) cultured on Matrigel-coated dishes. 
Photos were taken at two different magnification, 20X (A) and 40X (B).  
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Figure 11 
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Fig.11  Effect of 3,3’-Diiodothyronine (3,3’-T2) and 3,5-Diiodothyronine (3,5-T2) on total 
triglycerides level in human primary hepatocytes, assessed using a triglycerides determination kit 
as described in Materials and Methods section. Cells were treated for 24 h (A) and 48 h (B) with 
3,3’-T2 or 3,5-T2 before extracting lipids, as explained in Materials and Methods section. 
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Figure 12 
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Fig.12  Effect of 3,3’-Diiodothyronine (3,3’-T2) and 3,5-Diiodothyronine (3,5-T2) on total 
triglycerides level in human primary hepatocytes, assessed using a triglycerides determination kit 
as described in Materials and Methods section. Cells were treated for 24 h (A) and 72 h (B) with 
3,3’-T2 or 3,5-T2 before extracting lipids, as explained in Materials and Methods section. 
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Figure 13 
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Fig.13  Effect of 3,5-Diiodothyronine (3,5-T2) and 3,3’-Diiodothyronine (3,3’-T2) on Akt 
phosphorylation at Ser473 residue in human primary hepatocytes, assessed by Western Blot. 
Cells were treated for 10’ with 1 nM 3,5-T2 and 3,3’-T2. Western Blot was performed according 
to the procedure described in Materials and Methods section.  
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Figure 14  
 
 
 
 
                  
 
 
      
        
                    
 
 
 
 
 
 
 
Fig.14  Effect of 3,5-Diiodothyronine (3,5-T2) and 3,3’-Diiodothyronine (3,3’-T2) on FoxO1 
phosphorylation at Ser256 residue in human primary hepatocytes, assessed by Western Blot. 
Cells were treated for 10’ with 1 nM 3,5-T2 and 3,3’-T2. Western Blot was performed according 
to the procedure described in Materials and Methods section.  
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Figure 15 
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Fig.15  Effect of 3,3’-Diiodothyronine (3,3’-T2) on Akt phosphorylation at Ser473 residue in 
human primary hepatocytes after siRNA silencing of Rictor subunit of mTORC2 complex, 
assessed by Western Blot. Cells were silenced with siRNA(I) and then treated for 10’ with 3,3’-
T2 1 nM. Gene silencing and Western Blot were performed according to the procedure described 
in Materials and Methods section. 
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Figure 16   
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Fig.16  Effect of 3,3’-Diiodothyronine (3,3’-T2) on Akt phosphorylation at Ser473 residue in 
human primary hepatocytes after siRNA silencing of Rictor subunit of mTORC2 complex, 
assessed by Western Blot. Cells were silenced with siRNA(II) and siRNA(I+II), and then treated 
for 10’ with 3,3’-T2 1 nM. Gene silencing and Western Blot were performed according to the 
procedures described in Materials and Methods section.  
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Figure 17 
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Fig.17  Effect of 3,3’-Diiodothyronine (3,3’-T2) on Akt phosphorylation at Ser473 residue in 
human primary hepatocytes after treatment with a CtrlsiRNA (scramble), assessed by Western 
Blot. Cells were silenced with the CtrlsiRNA and then treated for 10’ with 3,3’-T2 1 nM. Gene 
silencing and Western Blot were performed according to the procedures described in Materials 
and Methods section.   
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Figure 18  
 
 
         
 
 
                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.18  Effect of 3,3’-Diiodothyronine (3,3’-T2) and on the levels of Rictor subunit of mTORC2 
in human primary hepatocytes after siRNA silencing of Rictor subunit of mTORC2 complex, 
assessed by Western Blot. Cells were silenced with siRNA(I), siRNA(II) and siRNA(I+II), and 
then treated for 10’ with 3,3’-T2 1 nM. Gene silencing and Western Blot were performed 
according to the procedures described in Materials and Methods section.  
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Figure 19  
 
 
  
       
 
 
 
 
                           
 
 
 
 
 
 
 
 
 
 
Fig.19  Effect of 3,3’-Diiodothyronine (3,3’-T2) on the levels of mTOR in human primary 
hepatocytes after siRNA silencing of Rictor subunit of mTORC2 complex, assessed by Western 
Blot. Cells were silenced with siRNA(I), siRNA(II) and siRNA(I+II), and then treated for 10’ 
with 3,3’-T2 1 nM. Gene silencing and Western Blot were performed according to the procedures 
described in Materials and Methods section.  
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DISCUSSION 
 
Taken together the results obtained in rat primary hepatocytes (RPH) show that the 
system we built can be considered a good experimental model to simulate a steatotic 
and insulin resistant liver, and hence to test the action of potentially therapeutic 
molecules. 
First of all our data demonstrate for the first time in an in vitro system that p85α 
subunit of PI3K is directly involved in the onset of insulin resistance, as previously 
described in vivo in mice (Mauvais-Jarvis F et al., 2002), in this way providing a new 
useful tool to study this topic and to test the efficacy of new therapeutic molecules. 
Analogously, we found an increase in PTEN levels, as already reported in endothelial 
cells and 3T3-L1 cells (Wang XL et al., 2006; Shen YH et al., 2006; Lee SK et al., 
2011), further substantiating our model. Interestingly, we also found an increase in the 
levels of Akt after oleic acid treatment, but actually we are not able to explain this 
observation, leaving this topic to successive analysis. In this system 3,5-
diiodothyronine in the range of physiological concentrations hugely reduces the 
amount of triglycerides, and induces phosphorylation of Akt at Ser473 residue, 
possibly activating insulin signaling pathway through a distinct pathway.       
For what concerns the role of fructose, these data support the idea that fructose per se, 
in the range of physiological concentrations, is not able to induce neither triglycerides 
accumulation nor insulin resistance, and several studies carried out in in vivo systems 
seem to be coherent with our observations. Studies carried out in vivo in rodents shown 
that high doses of fructose are responsible for an increased hepatic inflammation, in 
this way favouring the transition from a steatotic condition to steatohepatitis. In fact, in 
mice it has been demonstrated that a high-fructose diet is able to induce a TNFα-
110 
 
mediated steatosis and insulin resistance together with an increased neutrophil 
infiltration, suggesting that fructose may be involved in the onset of steatohepatitis as a 
proinflammatory agent (Kanuri G et al., 2011). Similarly it has been shown that a high 
fat coupled to a high fructose diet determines an increased hepatic ROS production and 
a NASH-like phenotype with significant fibrosis. The mechanism of fibrosis may 
involve an increased hepatic oxidative stress associated with hepatic macrophage 
aggregation, which in turn induces a TGFβ1-signaled collagen deposition and 
histologically evident hepatic fibrosis (Kohli R et al., 2010). Interestingly, a recent 
study carried out in mice suggests that a chronic intake of high doses of fructose is 
able to induce a huge bacterial overgrowth at the intestine level, that together with an 
increased permeability, finally results in an endotoxin-dependent activation of hepatic 
Kupffer cells, which can contribute to the onset of hepatic insulin resistance through a 
TNFα-mediated mechanism (Spruss A et al., 2009).  
These observations are thus consistent with our data, supporting the idea that fructose 
exerts detrimental effects only at very high doses, and not through a liver specific 
mechanism, but rather through systemic effects that trigger an increase of oxidative 
and inflammatory stress at the whole body level. These factors if associated with the 
other typical risk factors such as calories surplus coupled with high prevalence of fats 
in the diet and scarce physical activity, might constitute an additional stimulus towards 
progression to NASH. Quite unexpectedly, a very recent work demonstrates that in 
humans small doses of fructose (≤10 g/meal), may exert beneficial effects on 
glycaemic control without adverse effects on body weight, cardiovascular system, 
TAG levels, insulin and uric acid (Sievenpiper JL et al., 2012 [a]). 
For what concerns the data obtained with human primary hepatocytes (HPH), in my 
opinion they are very important for several reasons. First of all, the experimental 
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system used, HPH cultured on Matrigel, represents the most reliable reproduction of a 
real human liver that is actually possible to achieve, as already described in the 
analysis of other liver specific metabolic pathways (Ellis E et al., 1998; Ellis E et al., 
2001; Olsavsky KM et al., 2007). Secondly, in addition to confirm what observed in 
RPH for 3,5-diiodothyronine effect on triglyceride content and Akt phosphorylation, 
these results extend the analysis to FoxO1, in this way clarifying better the signal 
transduction pathway, and even more interestingly to 3,3’-diiodothyronine. Indeed, 
this diiodothyronine might be of greater therapeutic relevance if compared to 3,5-
diiodothyronine, considering that no thyromimetic effects have been found until now 
for 3,3’-T2, whereas it has been established that 3,5-T2 shares some effects with T3, 
even if of lesser magnitude (Ball SG et al., 1997). Thirdly, these data demonstrates for 
the first time that both 3,5-T2 and 3,3’-T2 are able to activate the insulin signaling 
pathway through an mTORC2 mediated mechanism, opening the way to several other 
very interesting future directions at basic and applied science level. From a basic 
science point of view, as described elsewhere in this thesis, no information is present 
until now about signals that could activate mTORC2, with the exception of a recent 
paper that demonstrate a direct activation mediated by PIP3 (Gan X et al., 2011). Thus 
our data might represent an interesting and useful starting point to deeply analyse this 
topic, trying to clarify which and how many additional pieces this mosaic owns. Two 
different hypotheses seem to be particularly promising in our opinion, the first being 
the potential involvement of a membrane receptor, in analogy to what described about 
the interaction between thyroxin and triiodothyronine and integrin αVβ3, the second 
the possible participation of a cytoplasmic TRβ1, as already described for 
triiodothyronine (Verga Falzacappa C et al., 2007; Verga Falzacappa C et al., 2009).  
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In the perspective of applied, translational research, these results offer an interesting 
future pharmaceutical tool to try to cope with obesity and type II diabetes, which are 
now considered new emerging epidemics in the field of metabolic diseases (Pischon T 
et al., 2008; Zimmet P et al., 2001). Several therapeutic approaches have been 
suggested to date for NAFLD, taking in account the different steps involved in the 
progression of this pathological condition. Primarily, several authors described the 
beneficial effects of lifestyle modifications, weight loss and physical activity, but also 
underlining the poor sustainability of weight loss and the difficulty to achieve a 
maintainable rate of physical activity in all patients (Harrison SA, Day CP, 2007; St. 
George A, et al., 2009; Johnson NA, George J, 2010). Moreover it is now becoming 
clear that adiposity, fat distribution and body weight regulation are processes that are, 
at least in part, under genetic control, suggesting that some people could be more 
predisposed to develop this kind of pathologies (Morton GJ, et al., 2006; Schwimmer 
JB et al., 2009; Lindgren CM et al., 2009; Willer CJ et al., 2009).  Nowadays several 
molecules are available that can be used to improve NAFLD clinical picture, such as 
pioglitazone and vitamin E, even if the results are not completely convincing, and 
some side effects, such as weight gain, have been described (Sanyal AJ et al., 2010).       
In this context the possible future use diiodothyronines, and in particular of 3,3’-
diiodothyronine, could offer a new tool in the management of NAFLD, to be used 
together with the lifestyle modifications described above and maybe with other dietary 
supplements. Diiodothyronines might have a positive role in improving the overall 
lipid profile of patients, especially reducing abdominal adiposity and intrahepatic fat, 
two widely recognised triggering factors of NAFLD, as well as of metabolic syndrome 
(Després JP, Lemieux I, 2006; Gastaldelli A et al., 2009; Fabbrini E et al., 2009; 
Fabbrini E et al., 2010). Moreover they may contribute to reactivate the insulin 
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signaling pathway, bypassing the classical IR-IRS1/2 steps, which are typically 
blocked in type 2 diabetes condition, as described in detail in the introduction. These 
aspects, in conjunction with the fact that diiodothyronines, but in particular 3,3’-
diiodothyronine, do not show the typical adverse effects that can arise after a thyroid 
hormone supplementation, permit us to be quite confident that in the future these 
molecules may help clinicians in improving NAFLD and metabolic diseases as well.             
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